[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1053
46. Boulanger E, Duprez R, Delabesse E, Gabarre J, Macintyre E, Gessain A: Mono/oligoclonal pattern of Kaposi Sarcoma-associated herpesvirus (KSHV/HHV-8) episomes in primary effusion lymphoma cells. Int J Cancer; 2005 Jul 1;115(4):511-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL) is a rare lymphoma of B-cell origin, developed in serous cavities.
  • PEL tumor cells are latently infected with Kaposi sarcoma-associated herpesvirus (KSHV) and in most cases co-infected with Epstein-Barr virus (EBV).
  • In 15 primary PEL tumors including 10 EBV-positive cases, we analyzed the fused terminal repeat (TR) regions of KSHV episomes using pulsed-field gel electrophoresis and Southern blot.
  • On the same genomic DNA samples, the cellular clonality was assessed by Southern blot and PCR detection of monoclonal immunoglobulin heavy chain (IGH) VDJ gene rearrangements, associated in the EBV-infected cases, with Southern blot analysis of the fused termini of EBV episomes.
  • Monoclonal IGH gene rearrangements were detected in 13 tumors using Southern blot, in 11 cases using PCR, and in all cases considering both methods.
  • However, only 5 PEL tumors were found to be monoclonally infected with KSHV.
  • We hypothesized that the apparent discrepancy between viral and cellular clonalities in PEL might be due to several phenomena including complex mechanisms of genomic recircularization, insertion of duplicated sequences into the TR region and simultaneous infection of tumor cells with defective KSHV variants.

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • [CommentIn] Int J Cancer. 2006 Oct 1;119(7):1746-8; author reply 1749-50 [16671085.001]
  • (PMID = 15700304.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


47. Gagne S, Lesage J, Ostiguy C, Cloutier Y, Van Tra H: Quantitative determination of hexamethylene diisocyanate (HDI), 2,4-toluene diisocyanate (2,4-TDI) and 2,6-toluene diisocyanate (2,6-TDI) monomers at ppt levels in air by alkaline adduct coordination ionspray tandem mass spectrometry. J Environ Monit; 2005 Feb;7(2):145-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative determination of hexamethylene diisocyanate (HDI), 2,4-toluene diisocyanate (2,4-TDI) and 2,6-toluene diisocyanate (2,6-TDI) monomers at ppt levels in air by alkaline adduct coordination ionspray tandem mass spectrometry.
  • Once sensitized, some workers could react to isocyanate monomers at concentrations below 1% of the Permissible Exposure Limit of 5 ppb in air.
  • Currently available methods are not sufficiently sensitive to adequately evaluate isocyanates present at these levels in workplace air.
  • The analytical method's linearity was measured for a concentration range varying from the limit of detection of 0.04-0.13 ng mL(-1), depending on the monomer, up to approximately 32 ng mL(-1) for every isocyanate monomer, all with correlation coefficients (R(2)) greater than 0.999.
  • The analytical method's lower limit of quantification combined with an adapted sampling strategy allow the quantification of isocyanate monomers down to 0.04 ppt for an 8 h work shift when a lithium adduct is used, which is more than 300 times lower than the most sensitive method currently available.
  • This novel method can be used to confirm the very low level of isocyanate monomers for the safe reassignment of sensitized workers and it is also useful for charting the isocyanate dispersion tail in workplace environments.

  • Hazardous Substances Data Bank. 2,4-TOLUENE DIISOCYANATE .
  • Hazardous Substances Data Bank. HEXAMETHYLENE DIISOCYANATE .
  • Hazardous Substances Data Bank. 2,6-TOLUENE DIISOCYANATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15690096.001).
  • [ISSN] 1464-0325
  • [Journal-full-title] Journal of environmental monitoring : JEM
  • [ISO-abbreviation] J Environ Monit
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Air Pollutants, Occupational; 0 / Cyanates; 0 / Isocyanates; 0I70A3I1UF / 1,6-hexamethylene diisocyanate; 17X7AFZ1GH / Toluene 2,4-Diisocyanate; 91-08-7 / 2,6-diisocyanatotoluene
  •  go-up   go-down


48. Cotte-Rodríguez I, Justes DR, Nanita SC, Noll RJ, Mulligan CC, Sanders NL, Cooks RG: Analysis of gaseous toxic industrial compounds and chemical warfare agent simulants by atmospheric pressure ionization mass spectrometry. Analyst; 2006 Apr;131(4):579-89
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The suitability of atmospheric pressure chemical ionization mass spectrometry as sensing instrumentation for the real-time monitoring of low levels of toxic compounds is assessed, especially with respect to public safety applications.
  • Tandem MS methods were implemented in selected cases for improved selectivity, sensitivity, and limits of detection.
  • Limits of detection in the parts-per-billion and parts-per-trillion range were achieved for this set of analytes.
  • In all cases detection limits were well below the compounds' permissible exposure limits (PELs), even in the presence of added complex mixtures of alkanes.

  • MedlinePlus Health Information. consumer health - Biodefense and Bioterrorism.
  • MedlinePlus Health Information. consumer health - Chemical Emergencies.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16568176.001).
  • [ISSN] 0003-2654
  • [Journal-full-title] The Analyst
  • [ISO-abbreviation] Analyst
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Air Pollutants; 0 / Chemical Warfare Agents
  •  go-up   go-down


49. Menier C, Guillard C, Cassinat B, Carosella ED, Rouas-Freiss N: HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera. Leukemia; 2008 Mar;22(3):578-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To examine this, we analyzed whether HLA-G5 affects the proliferation of UT7/EPO and HEL erythroleukemia cells and characterized the mechanism by which HLA-G5 influences erythropoietin receptor (EPOR) signaling.
  • We show that HLA-G5 inhibits the proliferation of UT7/EPO cells, the EPOR signaling of which is similar to that of normal erythroid progenitors.
  • Involvement of JAK2 in erythroid cell proliferation has been highlighted by the role of JAK2 V617F mutation in polycythemia vera (PV), a myeloproliferative disorder characterized by erythroid lineage overproduction.
  • Clinical relevance is provided by analysis of PV patients who carry JAK2 V617F mutation, showing that HLA-G5 inhibits the formation of erythropoietin-independent erythroid colonies.
  • [MeSH-minor] Cell Division / drug effects. Cell Line, Tumor / drug effects. Cell Line, Tumor / metabolism. Colony-Forming Units Assay. Erythroid Precursor Cells / drug effects. Erythropoietin / physiology. G1 Phase / drug effects. HLA-G Antigens. Humans. Janus Kinase 2 / antagonists & inhibitors. Janus Kinase 2 / genetics. Janus Kinase 2 / metabolism. Leukemia, Erythroblastic, Acute / pathology. Microspheres. Mutation, Missense. Phosphorylation / drug effects. Point Mutation. Protein Processing, Post-Translational / drug effects. Recombinant Fusion Proteins / pharmacology. STAT3 Transcription Factor / metabolism. STAT5 Transcription Factor / metabolism

  • Genetic Alliance. consumer health - Polycythemia vera.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18059484.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HLA Antigens; 0 / HLA-G Antigens; 0 / Histocompatibility Antigens Class I; 0 / Receptors, Erythropoietin; 0 / Recombinant Fusion Proteins; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / STAT5 Transcription Factor; 11096-26-7 / Erythropoietin; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


50. Wu X, Murphy P, Cunnick J, Hendrich S: Synthesis and characterization of deoxynivalenol glucuronide: its comparative immunotoxicity with deoxynivalenol. Food Chem Toxicol; 2007 Oct;45(10):1846-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cytotoxicity of DON and DONGLU were compared in cell culture using human erythroleukemia cell line K562.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • Hazardous Substances Data Bank. DEOXYNIVALENOL .
  • Hazardous Substances Data Bank. Trypan blue .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17507135.001).
  • [ISSN] 0278-6915
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Coloring Agents; 0 / Glucuronides; 0 / Tetrazolium Salts; 0 / Thiazoles; 0 / Trichothecenes; 298-93-1 / thiazolyl blue; EC 3.2.1.31 / Glucuronidase; I2ZWO3LS3M / Trypan Blue; JT37HYP23V / deoxynivalenol
  •  go-up   go-down


56. Ades S, Maxfield LF, Gould CJ, Jones GK, Levy SB: Selection of non-P-glycoprotein mediated high-level etoposide resistant cell lines by adriamycin with P-gp inhibitors. Int J Oncol; 2006 Mar;28(3):747-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selection of non-P-glycoprotein mediated high-level etoposide resistant cell lines by adriamycin with P-gp inhibitors.
  • In murine erythroleukemia (MEL) A20 cells (grown in 20 ng/ml adriamycin), mutation(s) producing 10-fold adriamycin (doxorubicin) resistance emerged via an unknown mechanism.
  • Exposure of A20 cells to further stepwise increasing concentrations of ADR in combination with MDR modulators (PSC833 and verapamil) aimed to amplify the undetermined A20 mechanism while controlling P-glycoprotein (P-gp) overexpression.
  • Resistance to vincristine was unchanged, but resistance to etoposide (VP-16) was 3.7-fold higher in A40P than A20 (itself 97-fold higher than wild-type).
  • No mutations in the coding sequence of topoisomerase IIalpha could be located to account for the high etoposide resistance levels.
  • [MeSH-minor] ATP Binding Cassette Transporter, Sub-Family B / antagonists & inhibitors. ATP Binding Cassette Transporter, Sub-Family B / genetics. ATP Binding Cassette Transporter, Sub-Family B / metabolism. ATP-Binding Cassette Transporters / genetics. ATP-Binding Cassette Transporters / metabolism. Animals. Antigens, Neoplasm / genetics. Antigens, Neoplasm / metabolism. Antineoplastic Agents / pharmacology. Blotting, Western. Cell Line, Tumor. Cell Survival / drug effects. Cyclosporins / pharmacology. DNA Topoisomerases, Type II / genetics. DNA Topoisomerases, Type II / metabolism. DNA-Binding Proteins / genetics. DNA-Binding Proteins / metabolism. Daunorubicin / pharmacology. Dose-Response Relationship, Drug. Drug Resistance, Multiple / genetics. Gene Expression Regulation, Neoplastic / drug effects. Mice. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Verapamil / pharmacology

  • Hazardous Substances Data Bank. VERAPAMIL HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16465381.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / P-30 DK 34928
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / ATP Binding Cassette Transporter, Sub-Family B; 0 / ATP-Binding Cassette Transporters; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / Cyclosporins; 0 / DNA-Binding Proteins; 0 / RNA, Messenger; 0 / multidrug resistance protein 3; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; CJ0O37KU29 / Verapamil; EC 5.99.1.3 / DNA Topoisomerases, Type II; Q7ZP55KF3X / valspodar; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


57. Won JH, Han SH, Bae SB, Kim CK, Lee NS, Lee KT, Park SK, Hong DS, Lee DW, Park HS: Successful eradication of relapsed primary effusion lymphoma with high-dose chemotherapy and autologous stem cell transplantation in a patient seronegative for human immunodeficiency virus. Int J Hematol; 2006 May;83(4):328-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL) is a recently recognized disease that occurs most often in immunosuppressed patients, either with human immunodeficiency virus (HIV) or in the posttransplantation setting, and it occasionally occurs in nonimmunosuppressed patients.
  • PEL rarely responds to systemic chemotherapy, and the prognosis is poor, with a median survival time of less than 6 months for most cohorts.
  • A standard treatment for PEL has not yet been identified.
  • We describe a patient with HIV-seronegative PEL who relapsed after combination chemotherapy and then underwent successful treatment with high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT).
  • The treatment was well tolerated, and the patient has been in remission for 12 months after HDC and ASCT.
  • [MeSH-minor] Disease-Free Survival. HIV Seropositivity. Humans. Male. Middle Aged. Prognosis. Recurrence. Transplantation, Autologous


58. Dei S, Budriesi R, Sudwan P, Ferraroni M, Chiarini A, Garnier-Suillerot A, Manetti D, Martelli C, Scapecchi S, Teodori E: Diphenylcyclohexylamine derivatives as new potent multidrug resistance (MDR) modulators. Bioorg Med Chem; 2005 Feb 15;13(4):985-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A series of compounds with a diphenylmethyl cyclohexyl skeleton, loosely related to verapamil, has been synthesized and tested as MDR modulators on anthracycline-resistant erythroleukemia K 562 cells.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15670906.001).
  • [ISSN] 0968-0896
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclohexylamines
  •  go-up   go-down


59. Vorobiev DS, Kiselevskii MV, Chikileva IO, Semenova IB: Effect of recombinant heat shock protein 70 of mycobacterial origin on cytotoxic activity and immunophenotype of human peripheral blood mononuclear leukocytes. Bull Exp Biol Med; 2009 Jul;148(1):64-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recombinant heat shock protein of mycobacterial origin with a molecular weight 70 kDa in concentration 0.1 microg/ml in vitro activates cytotoxic activity of mononuclear lymphocytes from peripheral blood of healthy donors against K-562 human erythroblastic leukemia cells sensitive to natural killers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19902099.001).
  • [ISSN] 1573-8221
  • [Journal-full-title] Bulletin of experimental biology and medicine
  • [ISO-abbreviation] Bull. Exp. Biol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Heat-Shock Proteins; 0 / Recombinant Proteins
  •  go-up   go-down


60. Rush M, Appanah R, Lee S, Lam LL, Goyal P, Lorincz MC: Targeting of EZH2 to a defined genomic site is sufficient for recruitment of Dnmt3a but not de novo DNA methylation. Epigenetics; 2009 Aug 16;4(6):404-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting of EZH2 to a defined genomic site is sufficient for recruitment of Dnmt3a but not de novo DNA methylation.
  • Polycomb-mediated gene silencing and DNA methylation underlie many epigenetic processes important in normal development as well as in cancer.
  • Interestingly, however, the majority of H3K27me3 marked genes lack DNA methylation in ES cells, indicating that EZH2 recruitment may not be sufficient to promote DNA methylation.
  • Here, we employed a Gal4DBD/gal4UAS-based system to directly test if EZH2 binding at a defined genomic site is sufficient to promote de novo DNA methylation in a murine erythroleukaemia cell line.
  • Targeting of a Gal4DBD-EZH2 fusion to an intergenic transgene bearing a gal4 binding-site array promoted localized recruitment of Suz12 and Bmi1, subunits of PRC2 and PRC1, respectively, and deposition of H3K27me3.
  • Strikingly, while Dnmt3a was also recruited in an EZH2-dependent manner, de novo DNA methylation of the transgene was not observed.
  • Thus, while targeting of EZH2 to a specific genomic site is sufficient for recruitment of Dnmt3a, additional events are required for de novo DNA methylation.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. L-Lysine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19717977.001).
  • [ISSN] 1559-2308
  • [Journal-full-title] Epigenetics
  • [ISO-abbreviation] Epigenetics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histones; 0 / Polycomb-Group Proteins; 0 / Recombinant Fusion Proteins; 0 / Repressor Proteins; EC 2.1.1.37 / DNA (Cytosine-5-)-Methyltransferase; EC 2.1.1.37 / DNA methyltransferase 3A; EC 2.1.1.43 / Ezh2 protein, mouse; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 2.1.1.43 / Polycomb Repressive Complex 2; K3Z4F929H6 / Lysine
  •  go-up   go-down


61. Karikó K, Buckstein M, Ni H, Weissman D: Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity; 2005 Aug;23(2):165-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We show that RNA signals through human TLR3, TLR7, and TLR8, but incorporation of modified nucleosides m5C, m6A, m5U, s2U, or pseudouridine ablates activity.

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Immunity. 2005 Aug;23(2):111-3 [16111629.001]
  • (PMID = 16111635.001).
  • [ISSN] 1074-7613
  • [Journal-full-title] Immunity
  • [ISO-abbreviation] Immunity
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI060505; United States / NIAID NIH HHS / AI / AI50484; United States / NIDCR NIH HHS / DE / DE14825
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers; 0 / CD83 antigen; 0 / Cytokines; 0 / HLA-DR Antigens; 0 / Immunoglobulins; 0 / Membrane Glycoproteins; 0 / Nucleosides; 0 / Phosphatidylethanolamines; 0 / Receptors, Cell Surface; 0 / TLR3 protein, human; 0 / TLR7 protein, human; 0 / TLR8 protein, human; 0 / Toll-Like Receptor 3; 0 / Toll-Like Receptor 7; 0 / Toll-Like Receptor 8; 0 / Toll-Like Receptors; 63231-63-0 / RNA; 76391-83-8 / 1,2-dielaidoylphosphatidylethanolamine
  •  go-up   go-down


62. Liao J, Gallas M, Pegram M, Slingerland J: Lapatinib: new opportunities for management of breast cancer. Breast Cancer (Dove Med Press); 2010;2:79-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Approximately 20% of new diagnosed breast cancers overexpress the human epidermal growth factor receptor 2 (EGFR2), also known as erythroblastic leukemia viral oncogene homolog 2 (ERBB2) protein, as a consequence of ERBB2 gene amplification, resulting in a poor prognosis.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24367169.001).
  • [ISSN] 1179-1314
  • [Journal-full-title] Breast cancer (Dove Medical Press)
  • [ISO-abbreviation] Breast Cancer (Dove Med Press)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3846530
  • [Keywords] NOTNLM ; ERBB family / ERBB2 / breast cancer / capecitabine / lapatinib / letrozole / trastuzumab
  •  go-up   go-down


63. Kishimoto S, Nakamura S, Hattori H, Nakamura S, Oonuma F, Kanatani Y, Tanaka Y, Mori Y, Harada Y, Tagawa M, Ishihara M: Human stem cell factor (SCF) is a heparin-binding cytokine. J Biochem; 2009 Mar;145(3):275-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, pre-immobilized SCF on F/P MP-coated plates significantly stimulated proliferation of a human erythroleukemia cell line.

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • Hazardous Substances Data Bank. HEPARIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19074504.001).
  • [ISSN] 1756-2651
  • [Journal-full-title] Journal of biochemistry
  • [ISO-abbreviation] J. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Disaccharides; 0 / Stem Cell Factor; 9005-49-6 / Heparin
  •  go-up   go-down


6
Advertisement
4. Glaister BC, Orendurff MS, Schoen JA, Klute GK: Rotating horizontal ground reaction forces to the body path of progression. J Biomech; 2007;40(15):3527-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When studying the biomechanics of a transient turn, the orientation of the body will change relative to the orientation of the force plates over the progression of the turn.
  • Body reference frames were chosen whose origins were the center of mass (COM) and the pelvis origin (PEL).
  • A finite-difference method was used to align the axes of the reference frames according to the horizontal paths of the COM and PEL.
  • The ground reaction impulses (GRIs) were calculated relative to the COM and PEL reference frames.
  • GRI differences were small between the PEL and COM frames, suggesting that either is acceptable for turning studies.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17597134.001).
  • [ISSN] 0021-9290
  • [Journal-full-title] Journal of biomechanics
  • [ISO-abbreviation] J Biomech
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


65. Léger DY, Battu S, Liagre B, Cardot PJ, Beneytout JL: Sedimentation field flow fractionation to study human erythroleukemia cell megakaryocytic differentiation after short period diosgenin induction. J Chromatogr A; 2007 Jul 20;1157(1-2):309-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sedimentation field flow fractionation to study human erythroleukemia cell megakaryocytic differentiation after short period diosgenin induction.
  • It concerns the study of megakaryocytic differentiation processes after a short exposure to an inducting agent (diosgenin).
  • A short exposure to diosgenin was able to induce complete differentiation leading to maximal maturation which ended naturally after 192h incubation without the influence of a secondary effect of diosgenin.
  • [MeSH-major] Cell Differentiation. Diosgenin / metabolism. Leukemia, Erythroblastic, Acute / pathology. Megakaryocytes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17499257.001).
  • [ISSN] 0021-9673
  • [Journal-full-title] Journal of chromatography. A
  • [ISO-abbreviation] J Chromatogr A
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA Primers; 0 / RNA, Neoplasm; K49P2K8WLX / Diosgenin
  •  go-up   go-down


66. Régnier-Rosencher E, Barrou B, Marcelin AG, Jacobzone-Leveque C, Cadranel J, Leblond V, Francès C: [Primary effusion lymphoma in two kidney transplant recipients]. Ann Dermatol Venereol; 2010 Apr;137(4):285-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Primary effusion lymphoma (PEL) is a highly malignant non-Hodgkin lymphoma associated with Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8 infection (KSHV/HHV-8).
  • OBSERVATION: We describe two male kidney transplant recipients, aged 47 and 51 years, followed for Kaposi's sarcoma in skin, lymph nodes, gastrointestinal (GI) tract and lung whose disease was poorly controlled by sirolimus and chemotherapy.
  • CONCLUSION: The contrast between a very low KHSV viral load in plasma and a very high viral load pleural effusion should alert physicians and prompt suspicion of PEL in Kaposi's sarcoma patients with recurrent serous effusion.
  • The potential inhibitory role of sirolimus on PEL progression is discussed.
  • [MeSH-minor] Digestive System Neoplasms / drug therapy. Digestive System Neoplasms / secondary. Digestive System Neoplasms / virology. Fatal Outcome. Giant Lymph Node Hyperplasia / complications. Giant Lymph Node Hyperplasia / virology. Humans. Immunocompromised Host. Kidney Failure, Chronic / etiology. Kidney Failure, Chronic / surgery. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lung Neoplasms / virology. Lymphatic Metastasis. Male. Middle Aged. Pleural Effusion, Malignant / cytology. Pleural Effusion, Malignant / virology. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / etiology. Sarcoma, Kaposi / virology. Skin Neoplasms / drug therapy. Skin Neoplasms / etiology. Skin Neoplasms / virology. Viral Load

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20417362.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


67. Liao CH, Fett W, Tzean SS, Hoffman G: Detection and sequence analysis of an altered pectate lyase gene in Pseudomonas syringae pv. glycinea and related bacteria. Can J Microbiol; 2006 Nov;52(11):1051-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection and sequence analysis of an altered pectate lyase gene in Pseudomonas syringae pv. glycinea and related bacteria.
  • Pectate lyase (PL) is a potent cell wall-degrading enzyme known to play a role in the microbial infection of plants.
  • However, the PL gene (pel) was detected by Southern hybridization in four out of four P. syringae pv. glycinea strains examined.
  • A P. syringae pv. glycinea pel gene was cloned, sequenced, and predicted to encode a protein sharing 70%-90% identity in amino acid sequence with PLs produced by pectolytic pseudomonads and xanthomonads.
  • A series of amino acid and nucleotide sequence analyses reveal that (i) the predicted P. syringae pv. glycinea PL contains two regions in the amino acid sequence that may affect the formation of a beta-helix structure important for the enzyme activity, and (ii) the P. syringae pv. glycinea pel gene contains a single-base insertion, a double-base insertion, and an 18-bp deletion, which can lead to the synthesis of an inactive PL protein.
  • The altered pel sequence was also detected by polymerase chain reaction and nucleotide sequencing in the genomes of other pathovars of P. syringae, including phaseolicola and tagetis.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17215896.001).
  • [ISSN] 0008-4166
  • [Journal-full-title] Canadian journal of microbiology
  • [ISO-abbreviation] Can. J. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] EC 4.2.2.- / Polysaccharide-Lyases; EC 4.2.2.2 / pectate lyase
  •  go-up   go-down


68. Comelli M, Genero N, Mavelli I: Caspase-independent apoptosis in Friend's erythroleukemia cells: role of mitochondrial ATP synthesis impairment in relocation of apoptosis-inducing factor and endonuclease G. J Bioenerg Biomembr; 2009 Feb;41(1):49-59
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caspase-independent apoptosis in Friend's erythroleukemia cells: role of mitochondrial ATP synthesis impairment in relocation of apoptosis-inducing factor and endonuclease G.
  • We previously documented that parental and differentiated Friend's erythroleukemia cells were induced to apoptosis by oligomycin and H(2)O(2) exposure, showing that the energy impairment occurring in both cases as a consequence of a severe mitochondrial F(0)F(1)ATPsynthase inactivation was a common early feature.
  • No detectable change in mitochondrial transmembrane potential and no variation in mitochondrial levels of Bcl-2 and Bax are observed.
  • These results point to the osmotic rupture of the mitochondrial outer membrane as occurring in response to cell exposure to the two energy-impairing treatments under conditions preserving the mitochondrial inner membrane.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1997 Feb 21;275(5303):1129-32 [9027314.001]
  • [Cites] Cell Mol Life Sci. 2001 Mar;58(3):356-70 [11315185.001]
  • [Cites] EMBO J. 1998 Jan 2;17(1):37-49 [9427739.001]
  • [Cites] J Neurosci. 1999 Sep 1;19(17):7394-404 [10460246.001]
  • [Cites] J Exp Med. 1998 Apr 20;187(8):1261-71 [9547337.001]
  • [Cites] Nature. 1999 Jun 3;399(6735):483-7 [10365962.001]
  • [Cites] FEBS Lett. 1998 Apr 10;426(1):111-6 [9598989.001]
  • [Cites] Biochimie. 2002 Feb-Mar;84(2-3):131-41 [12022944.001]
  • [Cites] Biochem Biophys Res Commun. 1985 Mar 29;127(3):1039-44 [3985951.001]
  • [Cites] Biophys J. 1988 May;53(5):785-94 [3390520.001]
  • [Cites] Trends Cell Biol. 2000 Sep;10(9):369-77 [10932094.001]
  • [Cites] Biol Pharm Bull. 2007 Aug;30(8):1516-22 [17666813.001]
  • [Cites] Nat Med. 2005 Jul;11(7):725-30 [16015365.001]
  • [Cites] J Neurosci. 1999 Aug 1;19(15):6235-47 [10414953.001]
  • [Cites] EMBO J. 2003 Sep 1;22(17):4385-99 [12941691.001]
  • [Cites] Cell. 2004 Jun 11;117(6):773-86 [15186778.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3668-72 [9108035.001]
  • [Cites] Free Radic Biol Med. 2003 May 1;34(9):1190-9 [12706499.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Sep 17;322(2):355-63 [15325238.001]
  • [Cites] Cell. 1993 Oct 22;75(2):241-51 [7503812.001]
  • [Cites] Trends Biochem Sci. 2001 Feb;26(2):112-7 [11166569.001]
  • [Cites] Science. 2004 Jul 30;305(5684):626-9 [15286356.001]
  • [Cites] Blood. 1996 May 1;87(9):3837-43 [8611710.001]
  • [Cites] Biochemistry. 1991 May 7;30(18):4480-6 [2021638.001]
  • [Cites] Cell. 1997 Nov 28;91(5):627-37 [9393856.001]
  • [Cites] Physiol Rev. 2007 Jan;87(1):99-163 [17237344.001]
  • [Cites] Am J Physiol Cell Physiol. 2003 Dec;285(6):C1483-93 [12930708.001]
  • [Cites] J Clin Invest. 2005 Oct;115(10):2640-7 [16200197.001]
  • [Cites] Cell. 1997 Nov 14;91(4):479-89 [9390557.001]
  • [Cites] J Biol Chem. 1998 Nov 6;273(45):29540-4 [9792662.001]
  • [Cites] Biochim Biophys Acta. 1995 Jul 17;1241(2):139-76 [7640294.001]
  • [Cites] Nat Chem Biol. 2005 Sep;1(4):188-9 [16408030.001]
  • [Cites] Genes Dev. 2001 Nov 15;15(22):2922-33 [11711427.001]
  • [Cites] Science. 1997 Feb 21;275(5303):1132-6 [9027315.001]
  • [Cites] FEBS Lett. 2001 Jul 6;500(3):114-8 [11445067.001]
  • [Cites] J Biol Chem. 2008 Feb 29;283(9):5622-31 [18167347.001]
  • [Cites] Acta Pharmacol Sin. 2004 Jan;25(1):83-9 [14704127.001]
  • [Cites] EMBO J. 2005 Apr 6;24(7):1375-86 [15775970.001]
  • [Cites] Free Radic Biol Med. 2005 Jan 1;38(1):12-23 [15589367.001]
  • [Cites] Nature. 2000 Aug 24;406(6798):855-62 [10972280.001]
  • [Cites] EMBO J. 1998 Jul 15;17(14):3878-85 [9670005.001]
  • [Cites] FEBS Lett. 1996 Jan 8;378(2):107-10 [8549813.001]
  • [Cites] Apoptosis. 2005 Oct;10(5):997-1007 [16151635.001]
  • [Cites] Cell Death Differ. 2000 Mar;7(3):282-91 [10745273.001]
  • [Cites] Mol Biol Cell. 2007 Jan;18(1):84-93 [17079734.001]
  • [Cites] Cell Death Differ. 2006 Aug;13(8):1396-402 [16710362.001]
  • [Cites] Nature. 2001 Mar 29;410(6828):549-54 [11279485.001]
  • [Cites] J Mol Biol. 2004 Apr 23;338(2):217-28 [15066427.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] Free Radic Biol Med. 1998 Apr;24(6):924-32 [9607602.001]
  • [Cites] Anal Biochem. 1989 May 15;179(1):1-7 [2667390.001]
  • [Cites] Biochem Soc Trans. 2000 Feb;28(2):170-7 [10816121.001]
  • [Cites] Cell Death Differ. 2005 Nov;12 Suppl 2:1478-80 [16247494.001]
  • [Cites] Dev Cell. 2002 Jan;2(1):55-67 [11782314.001]
  • [Cites] Trends Cell Biol. 2006 May;16(5):264-72 [16621561.001]
  • [Cites] J Cell Physiol. 2002 Aug;192(2):131-7 [12115719.001]
  • [Cites] FEBS Lett. 2004 Jan 16;557(1-3):14-20 [14741334.001]
  • [Cites] Nature. 1999 Feb 4;397(6718):441-6 [9989411.001]
  • [Cites] Cell Death Differ. 2001 Dec;8(12):1136-42 [11753562.001]
  • [Cites] FEBS Lett. 1994 Sep 19;352(1):71-5 [7925947.001]
  • [Cites] Science. 1993 Nov 19;262(5137):1274-7 [8235659.001]
  • [Cites] J Neurochem. 1996 Sep;67(3):1259-67 [8752134.001]
  • (PMID = 19184384.001).
  • [ISSN] 1573-6881
  • [Journal-full-title] Journal of bioenergetics and biomembranes
  • [ISO-abbreviation] J. Bioenerg. Biomembr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Inducing Factor; 8L70Q75FXE / Adenosine Triphosphate; EC 3.1.- / Endodeoxyribonucleases; EC 3.1.21.- / endonuclease G; EC 3.6.3.14 / Proton-Translocating ATPases
  •  go-up   go-down


69. Baniushin BF: [Methylation of adenine residues in DNA of eukaryotes]. Mol Biol (Mosk); 2005 Jul-Aug;39(4):557-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In plants m6A was detected in total, mitochondrial and nuclear DNAs; in plants one and the same gene (DRM2) can be methylated both at adenine and cytosine residues.
  • First N6-adenine DNA-methyltransferase (wadmtase) of higher eukaryotes was isolated from vacuolar fraction of vesicles obtained from aging wheat coleoptiles; in the presence of S-adenosyl-L-methionine this Mg2+ -, Ca2+ -dependent enzyme de novo methylates first adenine residue in TGATCA sequence in single- and double-stranded DNA but it prefers single-stranded DNA structures.
  • Adenine DNA methylation in eukaryotes seems to be involved in regulation of both gene expression and DNA replication including replication of mitochondrial DNA.
  • Thus, in eukaryotic cell there are, at least, two different systems of the enzymatic DNA methylations (adenine and cytosine ones) and a special type of regulation of gene functioning based on the combinatory hierarchy of these interdependent genome modifications.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16083005.001).
  • [ISSN] 0026-8984
  • [Journal-full-title] Molekuliarnaia biologiia
  • [ISO-abbreviation] Mol. Biol. (Mosk.)
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / DNA, Mitochondrial; EC 2.1.1.- / DNA Modification Methylases; JAC85A2161 / Adenine
  • [Number-of-references] 94
  •  go-up   go-down


70. Di Pietro R, di Giacomo V, Caravatta L, Sancilio S, Rana RA, Cataldi A: Cyclic nucleotide response element binding (CREB) protein activation is involved in K562 erythroleukemia cells differentiation. J Cell Biochem; 2007 Mar 1;100(4):1070-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclic nucleotide response element binding (CREB) protein activation is involved in K562 erythroleukemia cells differentiation.
  • K562 are human erythroleukemia cells inducible to differentiate into megakaryocytic or erythroid lineage by different agents.
  • Cyclic nucleotide Response Element Binding (CREB) protein, a nuclear transcription factor which mediates c-AMP signaling, is a potential candidate involved in the occurrence of erythroid differentiation and adaptive response.
  • Here we investigated signaling events in K562 cells induced with 30 microM hemin to undergo erythroid differentiation.
  • All in all these results document a novel relationship between CREB activation and differentiation-related apoptotic cell death and assign a role to p38 MAP kinase pathway in determining these events in K562 erythroleukemia cells.
  • [MeSH-minor] Apoptosis / drug effects. Blotting, Western. Hemin / pharmacology. Humans. Imidazoles / pharmacology. K562 Cells. Leukemia, Erythroblastic, Acute / metabolism. Leukemia, Erythroblastic, Acute / pathology. Microscopy, Fluorescence. Phosphorylation / drug effects. Pyridines / pharmacology. Serine / metabolism. p38 Mitogen-Activated Protein Kinases / metabolism

  • Hazardous Substances Data Bank. L-SERINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17063485.001).
  • [ISSN] 0730-2312
  • [Journal-full-title] Journal of cellular biochemistry
  • [ISO-abbreviation] J. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclic AMP Response Element-Binding Protein; 0 / Imidazoles; 0 / Pyridines; 0 / SB 203580; 452VLY9402 / Serine; 743LRP9S7N / Hemin; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  •  go-up   go-down


71. Karim N, Jones JT, Okada H, Kikuchi T: Analysis of expressed sequence tags and identification of genes encoding cell-wall-degrading enzymes from the fungivorous nematode Aphelenchus avenae. BMC Genomics; 2009;10:525
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of expressed sequence tags and identification of genes encoding cell-wall-degrading enzymes from the fungivorous nematode Aphelenchus avenae.
  • This nematode is also found in association with plants but its ability to cause plant disease remains largely undetermined.
  • The taxonomic position and intermediate lifestyle of A. avenae make it an important model for studying the evolution of plant parasitism within the Nematoda.
  • Expressed sequence tag (EST) analysis may therefore be useful in providing an initial insight into the poorly understood genetic background of A. avenae.
  • In addition, 1,100 (40.7%) of the sequences were functionally classified using Gene Ontology (GO) hierarchy.
  • Similarity searches of the cluster sequences identified a set of genes with significant homology to genes encoding enzymes that degrade plant or fungal cell walls.
  • The full length sequences of two genes encoding glycosyl hydrolase family 5 (GHF5) cellulases and two pectate lyase genes encoding polysaccharide lyase family 3 (PL3) proteins were identified and characterized.
  • CONCLUSION: We have described at least 2,214 putative genes from A. avenae and identified a set of genes encoding a range of cell-wall-degrading enzymes.
  • The presence of genes encoding a battery of cell-wall-degrading enzymes in A. avenae and their similarities with genes from other plant parasitic nematodes suggest that this nematode can act not only as a fungal feeder but also a plant parasite.
  • Further studies on genes encoding cell-wall-degrading enzymes in A. avenae will accelerate our understanding of the complex evolutionary histories of plant parasitism and the use of genes obtained by horizontal gene transfer from prokaryotes.
  • [MeSH-minor] Amino Acid Sequence. Animals. Base Sequence. Cellulase / genetics. Cluster Analysis. Databases, Protein. Desiccation. Gene Expression Regulation. Gene Library. Molecular Sequence Data. Phylogeny. Polysaccharide-Lyases / chemistry. Polysaccharide-Lyases / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Stress, Physiological / genetics

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Mol Biol. 2004 Jul 16;340(4):783-95 [15223320.001]
  • [Cites] Bioinformatics. 2004 Jun 12;20(9):1398-404 [14988115.001]
  • [Cites] FEBS Lett. 2004 Aug 13;572(1-3):201-5 [15304348.001]
  • [Cites] Mol Biochem Parasitol. 1985 Oct;17(1):93-104 [3932852.001]
  • [Cites] Mol Biochem Parasitol. 1987 Oct;25(3):267-72 [3696175.001]
  • [Cites] Mol Biochem Parasitol. 1992 Feb;50(2):285-94 [1741016.001]
  • [Cites] Mol Biochem Parasitol. 1993 Apr;58(2):317-23 [8479456.001]
  • [Cites] Exp Parasitol. 1993 Sep;77(2):155-61 [8375484.001]
  • [Cites] J Biol Chem. 1996 Jan 19;271(3):1441-7 [8576136.001]
  • [Cites] Genome Res. 1997 Oct;7(10):986-95 [9331369.001]
  • [Cites] J Bacteriol. 1997 Dec;179(23):7321-30 [9393696.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):4906-11 [9560201.001]
  • [Cites] Gene. 1998 Oct 5;220(1-2):61-70 [9767113.001]
  • [Cites] Science. 1998 Dec 11;282(5396):2012-8 [9851916.001]
  • [Cites] Mol Plant Microbe Interact. 1999 Jul;12(7):585-91 [10478479.001]
  • [Cites] FEBS Lett. 2005 Apr 25;579(11):2451-7 [15848187.001]
  • [Cites] Int J Parasitol. 2005 May;35(6):685-92 [15862581.001]
  • [Cites] Biochem J. 2005 May 15;388(Pt 1):151-7 [15631617.001]
  • [Cites] Biochem J. 2005 Jul 1;389(Pt 1):117-25 [15727561.001]
  • [Cites] Bioinformatics. 2005 Sep 15;21(18):3674-6 [16081474.001]
  • [Cites] J Biol Chem. 2005 Dec 9;280(49):40845-56 [16186127.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D16-20 [16381837.001]
  • [Cites] Parasitology. 2004;128 Suppl 1:S49-70 [16454899.001]
  • [Cites] Mol Plant Microbe Interact. 2006 Mar;19(3):280-7 [16570658.001]
  • [Cites] Mol Biol Evol. 2006 Sep;23(9):1792-800 [16790472.001]
  • [Cites] Gene. 2006 Nov 1;382:121-8 [16962258.001]
  • [Cites] Mol Phylogenet Evol. 2007 Mar;42(3):622-36 [17084644.001]
  • [Cites] Mol Biochem Parasitol. 2007 Sep;155(1):9-17 [17560668.001]
  • [Cites] WormBook. 2006;:1-10 [18023127.001]
  • [Cites] Nucleic Acids Res. 2008 Jul 1;36(Web Server issue):W465-9 [18424797.001]
  • [Cites] Nat Biotechnol. 2008 Aug;26(8):909-15 [18660804.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14802-7 [18809916.001]
  • [Cites] BMC Evol Biol. 2008;8:305 [18980666.001]
  • [Cites] BMC Genomics. 2009;10:69 [19203352.001]
  • [Cites] Mol Plant Microbe Interact. 2002 Jun;15(6):549-56 [12059103.001]
  • [Cites] Genome Res. 1999 Nov;9(11):1026-39 [10568743.001]
  • [Cites] Nat Genet. 2000 May;25(1):25-9 [10802651.001]
  • [Cites] Nature. 2000 Jul 6;406(6791):36-7 [10894530.001]
  • [Cites] Mol Plant Microbe Interact. 2001 Jan;14(1):63-71 [11194873.001]
  • [Cites] Parasitology. 2001 Jul;123(Pt 1):77-83 [11467786.001]
  • [Cites] Nature. 2002 Mar 7;416(6876):38 [11882885.001]
  • [Cites] Nucleic Acids Res. 2002 Apr 1;30(7):e32 [11917038.001]
  • [Cites] FEBS Lett. 2002 Jul 3;522(1-3):109-12 [12095628.001]
  • [Cites] Int J Parasitol. 2002 Sep;32(10):1293-300 [12204229.001]
  • [Cites] Bioinformatics. 2003 Feb 12;19(3):390-5 [12584125.001]
  • [Cites] Genome Biol. 2003;4(6):R39 [12801413.001]
  • [Cites] J Parasitol. 2003 Aug;89(4):761-6 [14533688.001]
  • [Cites] BMC Bioinformatics. 2002 Oct 25;3:31 [12398795.001]
  • [Cites] Nature. 2004 Jan 1;427(6969):30 [14702076.001]
  • [Cites] Genome Res. 2004 Feb;14(2):209-20 [14762059.001]
  • [Cites] Eukaryot Cell. 2004 Aug;3(4):966-75 [15302829.001]
  • (PMID = 19917084.001).
  • [ISSN] 1471-2164
  • [Journal-full-title] BMC genomics
  • [ISO-abbreviation] BMC Genomics
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AB495300/ AB495301/ AB495302/ AB495303/ AB495304/ AB495305/ AB495306/ AB495307/ GO479265/ GO484340
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 3.2.1.4 / Cellulase; EC 4.2.2.- / Polysaccharide-Lyases; EC 4.2.2.2 / pectate lyase
  • [Other-IDs] NLM/ PMC2784482
  •  go-up   go-down


72. Fuchs R, Stelzer I, Haas HS, Leitinger G, Schauenstein K, Sadjak A: The alpha1-adrenergic receptor antagonists, benoxathian and prazosin, induce apoptosis and a switch towards megakaryocytic differentiation in human erythroleukemia cells. Ann Hematol; 2009 Oct;88(10):989-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The alpha1-adrenergic receptor antagonists, benoxathian and prazosin, induce apoptosis and a switch towards megakaryocytic differentiation in human erythroleukemia cells.
  • The erythroleukemia cell lines K562 and human erythroleukemia (HEL) are established models to study erythroid and megakaryocytic differentiation in vitro.
  • Furthermore, both tested substances induced the expression of the megakaryocytic marker CD41a, whereas the expression of the erythroid marker glycophorin-a was decreased or unchanged.
  • Even though the expression of differentiation markers was similar after benoxathian and prazosin treatment in both cell lines, endomitosis of erythroleukemia cells was observed only after prazosin treatment.
  • In summary, these results indicate a possible role of alpha1-adrenergic receptor signaling in the regulation of erythroid and megakaryocytic differentiation, even though the receptor dependence of the observed effects needs further investigation.
  • [MeSH-major] Apoptosis / drug effects. Cell Differentiation / drug effects. Leukemia, Erythroblastic, Acute / drug therapy. Megakaryocytes / cytology. Oxathiins / pharmacology. Prazosin / pharmacology. Receptors, Adrenergic, alpha-1 / metabolism
  • [MeSH-minor] Adrenergic alpha-Antagonists / pharmacology. Cell Line, Tumor. Erythroid Cells. Humans. K562 Cells

  • Hazardous Substances Data Bank. PRAZOSIN HYDROCHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19241077.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Oxathiins; 0 / Receptors, Adrenergic, alpha-1; 92642-94-9 / benoxathian; XM03YJ541D / Prazosin
  •  go-up   go-down


73. Zoet YM, Eijsink C, Kardol MJ, Franke-van Dijk ME, Wilson GL, de Paus R, Mickelson E, Heemskerk M, van den Elsen PJ, Claas FH, Mulder A, Doxiadis II: The single antigen expressing lines (SALs) concept: an excellent tool for screening for HLA-specific antibodies. Hum Immunol; 2005 May;66(5):519-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Definition of the antibody specificity in the serum of patients waiting for a renal transplant or in need for platelet transfusion is a crucial step for finding adequate donors.
  • Confounding factors are the complexity of the serum antibodies and the expression of several, up to six, different human leukocyte antigens (HLA) on peripheral blood lymphocytes used as target cells in the antibody screening.
  • Single antigen-expressing (SAL) cell lines were generated by transfecting human major histocompatibility complex (MHC) class I sequences into K562, an erythroleukemia-derived cell line lacking MHC class I and II expression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15935889.001).
  • [ISSN] 0198-8859
  • [Journal-full-title] Human immunology
  • [ISO-abbreviation] Hum. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antibodies, Monoclonal; 0 / HLA Antigens; 0 / HLA-A2 Antigen; 0 / HLA-A3 Antigen; 0 / HLA-B7 Antigen; 0 / Histocompatibility Antigens Class I; 0 / Immunoglobulin G; 0 / Immunoglobulin M; 9007-36-7 / Complement System Proteins
  •  go-up   go-down


74. Murakami Y, Yamagoe S, Noguchi K, Takebe Y, Takahashi N, Uehara Y, Fukazawa H: Ets-1-dependent expression of vascular endothelial growth factor receptors is activated by latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus through interaction with Daxx. J Biol Chem; 2006 Sep 22;281(38):28113-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • LANA associated with Daxx in a PEL cell line infected with KSHV.
  • To address the physiological significance of this interaction, we focused on a Daxx-mediated VEGF receptor gene regulation.
  • We found that Daxx repressed Ets-1-dependent Flt-1/VEGF receptor-1 gene expression, and that LANA inhibited the repression by Daxx in a reporter assay.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16861237.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antigens, Viral; 0 / Carrier Proteins; 0 / DAXX protein, human; 0 / ETS1 protein, human; 0 / Nuclear Proteins; 0 / Proto-Oncogene Protein c-ets-1; 0 / latency-associated nuclear antigen; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  •  go-up   go-down


75. Ng PP, Helguera G, Daniels TR, Lomas SZ, Rodriguez JA, Schiller G, Bonavida B, Morrison SL, Penichet ML: Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor. Blood; 2006 Oct 15;108(8):2745-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor.
  • We have previously reported that an anti-human transferrin receptor IgG3-avidin fusion protein (anti-hTfR IgG3-Av) inhibits the proliferation of an erythroleukemia-cell line.
  • We have now found that anti-hTfR IgG3-Av also inhibits the proliferation of additional human malignant B and plasma cells.
  • [MeSH-minor] Amino Acid Chloromethyl Ketones / pharmacology. Apoptosis / drug effects. Caspase Inhibitors. Cell Line, Tumor. Cell Proliferation / drug effects. Cross-Linking Reagents. Deferoxamine / pharmacology. Humans. Iron / pharmacology. Leukemia, Plasma Cell / metabolism. Leukemia, Plasma Cell / pathology. Leukemia, Plasma Cell / therapy. Multiple Myeloma / metabolism. Multiple Myeloma / pathology. Multiple Myeloma / therapy. Recombinant Fusion Proteins / pharmacology. Siderophores / pharmacology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DESFERRIOXAMINE .
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1993 Dec;7(12):2019-25 [8255102.001]
  • [Cites] Blood. 1997 Jul 15;90(2):754-65 [9226176.001]
  • [Cites] Neurosurgery. 1997 Nov;41(5):1039-49; discussion 1049-51 [9361057.001]
  • [Cites] Eur J Haematol. 1997 Nov;59(5):318-26 [9414644.001]
  • [Cites] Clin Immunol Immunopathol. 1994 Jan;70(1):10-8 [7505211.001]
  • [Cites] Mol Immunol. 1994 Oct;31(15):1201-10 [7935507.001]
  • [Cites] J Immunol. 1995 Feb 15;154(4):1675-83 [7836751.001]
  • [Cites] Biochem J. 1996 Jun 15;316 ( Pt 3):777-86 [8670152.001]
  • [Cites] J Immunol. 1997 May 15;158(10):4797-804 [9144494.001]
  • [Cites] Int J Oncol. 1998 Oct;13(4):871-5 [9735419.001]
  • [Cites] Clin Cancer Res. 1995 Nov;1(11):1259-65 [9815920.001]
  • [Cites] Int J Oncol. 2000 Oct;17(4):643-51 [10995873.001]
  • [Cites] Haematologica. 2001 Mar;86(3):227-36 [11255268.001]
  • [Cites] Exp Hematol. 2001 Apr;29(4):441-7 [11301184.001]
  • [Cites] J Cell Biochem. 2001 Apr 2-27;82(1):171-86 [11400174.001]
  • [Cites] Blood. 2001 Aug 1;98(3):795-804 [11468181.001]
  • [Cites] Rev Clin Exp Hematol. 2001 Mar;5(1):3-14 [11486731.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):2264-9 [11854522.001]
  • [Cites] Nat Rev Cancer. 2001 Nov;1(2):118-29 [11905803.001]
  • [Cites] Curr Treat Options Oncol. 2001 Jun;2(3):205-16 [12057120.001]
  • [Cites] J Biol Chem. 2002 Jul 12;277(28):25568-75 [11980894.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10706-11 [12149472.001]
  • [Cites] Biochem Pharmacol. 2003 Jan 15;65(2):161-72 [12504792.001]
  • [Cites] Int J Cancer. 2003 Apr 20;104(4):400-8 [12584735.001]
  • [Cites] Biochim Biophys Acta. 2003 Mar 17;1620(1-3):225-34 [12595093.001]
  • [Cites] Cell Immunol. 2002 Dec;220(2):96-106 [12657244.001]
  • [Cites] Immunol Rev. 2003 Jun;193:10-21 [12752666.001]
  • [Cites] Free Radic Biol Med. 2003 Nov 15;35(10):1171-84 [14607516.001]
  • [Cites] J Neurooncol. 2003 Oct;65(1):3-13 [14649881.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1838-45 [14592824.001]
  • [Cites] Science. 2004 Jul 30;305(5684):626-9 [15286356.001]
  • [Cites] Lancet. 1980 Aug 23;2(8191):390-2 [6105517.001]
  • [Cites] Nature. 1980 Aug 28;286(5776):888-91 [7412870.001]
  • [Cites] Int J Cancer. 1981 Mar 15;27(3):329-34 [6270015.001]
  • [Cites] Nature. 1981 Nov 12;294(5837):171-3 [6272120.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Feb;79(4):1175-9 [6280171.001]
  • [Cites] Blood. 1982 Sep;60(3):703-13 [6286014.001]
  • [Cites] J Cell Physiol. 1982 Sep;112(3):403-10 [6290505.001]
  • [Cites] Biochem Biophys Res Commun. 1982 Oct 29;108(4):1495-501 [7181903.001]
  • [Cites] Int J Biochem Cell Biol. 1999 Oct;31(10):1111-37 [10582342.001]
  • [Cites] Lancet. 1983 Mar 5;1(8323):498-501 [6131211.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Jun;80(11):3494-8 [6304712.001]
  • [Cites] Blood. 1983 Oct;62(4):821-6 [6309286.001]
  • [Cites] Int J Cancer. 1983 Sep 15;32(3):343-9 [6309680.001]
  • [Cites] Cell Death Differ. 1999 Jun;6(6):516-24 [10381654.001]
  • [Cites] Cell Death Differ. 1999 Apr;6(4):362-9 [10381624.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3384-8 [10910043.001]
  • [Cites] J Cell Biol. 1983 Aug;97(2):508-21 [6309862.001]
  • [Cites] Cell Immunol. 1984 Jan;83(1):14-25 [6319033.001]
  • [Cites] Exp Cell Res. 1984 Feb;150(2):400-7 [6319165.001]
  • [Cites] Vox Sang. 1984;46(4):217-23 [6324490.001]
  • [Cites] J Biol Chem. 1984 Aug 25;259(16):10053-9 [6432778.001]
  • [Cites] Mol Cell Biol. 1984 Sep;4(9):1675-81 [6092931.001]
  • [Cites] Immunology. 1985 Feb;54(2):333-41 [2981766.001]
  • [Cites] J Clin Invest. 1985 Mar;75(3):1061-7 [2984253.001]
  • [Cites] J Immunol. 1985 Sep;135(3):1987-97 [2991374.001]
  • [Cites] Cancer Res. 1986 Apr;46(4 Pt 1):1759-63 [3004704.001]
  • [Cites] J Cell Biol. 1986 Mar;102(3):951-8 [3005341.001]
  • [Cites] Mol Cell Biol. 1985 Aug;5(8):1814-21 [3018527.001]
  • [Cites] Immunogenetics. 1986;24(3):163-70 [3489674.001]
  • [Cites] J Immunol. 1987 Apr 15;138(8):2422-6 [2951439.001]
  • [Cites] Ann N Y Acad Sci. 1987;507:187-98 [3327412.001]
  • [Cites] Prog Allergy. 1988;45:121-46 [3064093.001]
  • [Cites] Exp Cell Res. 1989 May;182(1):215-33 [2653853.001]
  • [Cites] J Oral Pathol Med. 1989 Dec;18(10):582-5 [2559980.001]
  • [Cites] Cancer Res. 1990 Oct 1;50(19):6295-301 [2400993.001]
  • [Cites] J Exp Med. 1992 Jun 1;175(6):1501-9 [1375263.001]
  • (PMID = 16804109.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K01 CA086915; United States / NCI NIH HHS / CA / R01 CA107023; United States / NCI NIH HHS / CA / CA 107023; United States / NCI NIH HHS / CA / CA 86915
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amino Acid Chloromethyl Ketones; 0 / Caspase Inhibitors; 0 / Cross-Linking Reagents; 0 / Immunoglobulin G; 0 / Receptors, Transferrin; 0 / Recombinant Fusion Proteins; 0 / Siderophores; 0 / benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone; 1405-69-2 / Avidin; E1UOL152H7 / Iron; J06Y7MXW4D / Deferoxamine
  • [Other-IDs] NLM/ PMC1895578
  •  go-up   go-down


76. Greene W, Kuhne K, Ye F, Chen J, Zhou F, Lei X, Gao SJ: Molecular biology of KSHV in relation to AIDS-associated oncogenesis. Cancer Treat Res; 2007;133:69-127
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • KSHV has been established as the causative agent of KS, PEL, and MCD, malignancies occurring more frequently in AIDS patients.
  • KSHV latent infection and lytic reactivation are characterized by distinct gene expression profiles, and both latency and lytic reactivation seem to be required for malignant progression.
  • As a sophisticated oncogenic virus, KSHV has evolved to possess a formidable repertoire of potent mechanisms that enable it to target and manipulate host cell pathways, leading to increased cell proliferation, increased cell survival, dysregulated angiogenesis, evasion of immunity, and malignant progression in the immunocompromised host.
  • The complex interplay between the two viruses dramatically elevates the risk for development of KSHV-induced malignancies, KS, PEL, and MCD.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Cancer Biol. 1999 Jun;9(3):201-9 [10343071.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4034-43 [10361100.001]
  • [Cites] J Virol. 1999 Jul;73(7):5556-67 [10364304.001]
  • [Cites] J Virol. 1999 Jul;73(7):5722-30 [10364323.001]
  • [Cites] J Virol. 1999 Aug;73(8):6892-902 [10400787.001]
  • [Cites] J Virol. 1999 Aug;73(8):6953-63 [10400794.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S58-65 [10430220.001]
  • [Cites] J Virol. 1999 Sep;73(9):7334-42 [10438822.001]
  • [Cites] Science. 1999 Aug 13;285(5430):1028-32 [10446041.001]
  • [Cites] J Gen Virol. 1999 Aug;80 ( Pt 8):2205-9 [10466820.001]
  • [Cites] J Infect Dis. 1999 Oct;180(4):1010-7 [10479125.001]
  • [Cites] J Virol. 1999 Oct;73(10):8268-78 [10482577.001]
  • [Cites] J Exp Med. 1999 Sep 20;190(6):827-40 [10499921.001]
  • [Cites] J Exp Med. 1999 Oct 4;190(7):1025-32 [10510092.001]
  • [Cites] AIDS. 1999 Oct 1;13(14):1851-5 [10513642.001]
  • [Cites] J Infect Dis. 1999 Nov;180(5):1466-76 [10515805.001]
  • [Cites] J Virol. 1999 Nov;73(11):9348-61 [10516043.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4984-9 [10519412.001]
  • [Cites] Oncogene. 1999 Oct 14;18(42):5738-46 [10523854.001]
  • [Cites] Acta Unio Int Contra Cancrum. 1962;18:330-63 [14481196.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3349-54 [15271792.001]
  • [Cites] J Biol Chem. 2004 Dec 10;279(50):51793-803 [15258150.001]
  • [Cites] Cancer Invest. 2004;22(5):774-86 [15581058.001]
  • [Cites] J Virol. 2005 Jan;79(2):800-11 [15613308.001]
  • [Cites] J Virol. 2005 Jan;79(2):1191-206 [15613346.001]
  • [Cites] J Virol. 2005 Feb;79(3):1397-408 [15650166.001]
  • [Cites] Blood. 2005 Feb 1;105(3):1310-8 [15471957.001]
  • [Cites] Immunity. 2005 Jan;22(1):59-70 [15664159.001]
  • [Cites] J Virol. 2005 Feb;79(4):2420-31 [15681443.001]
  • [Cites] Science. 2005 Feb 4;307(5710):739-41 [15692053.001]
  • [Cites] J Virol. 2005 Mar;79(6):3468-78 [15731241.001]
  • [Cites] J Virol. 2005 Mar;79(6):3479-87 [15731242.001]
  • [Cites] J Immunol. 2005 Mar 15;174(6):3686-94 [15749907.001]
  • [Cites] Chest. 2005 Mar;127(3):762-7 [15764755.001]
  • [Cites] J Virol. 2005 Apr;79(8):4651-63 [15795251.001]
  • [Cites] J Virol. 2005 May;79(9):5640-52 [15827179.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5570-5 [15800047.001]
  • [Cites] J Clin Invest. 2005 May;115(5):1369-78 [15864354.001]
  • [Cites] Blood. 2005 May 15;105(10):3987-94 [15665117.001]
  • [Cites] Nat Methods. 2005 Apr;2(4):269-76 [15782219.001]
  • [Cites] J Virol. 2005 Jun;79(12):7453-65 [15919901.001]
  • [Cites] J Virol. 2005 Jul;79(14):8750-63 [15994769.001]
  • [Cites] J Virol. 2005 Jul;79(14):9301-5 [15994824.001]
  • [Cites] J Biol Chem. 2005 Jul 15;280(28):26216-24 [15878864.001]
  • [Cites] Int J Cancer. 1998 Aug 12;77(4):543-8 [9679756.001]
  • [Cites] Nature. 1998 Aug 6;394(6693):588-92 [9707121.001]
  • [Cites] Lab Invest. 1998 Aug;78(8):949-55 [9714182.001]
  • [Cites] Cytokine Growth Factor Rev. 1998 Mar;9(1):63-83 [9720757.001]
  • [Cites] Transplant Proc. 1998 Aug;30(5):2095-6 [9723403.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10866-71 [9724796.001]
  • [Cites] Br J Haematol. 1998 Sep;102(4):1081-9 [9734661.001]
  • [Cites] J Virol. 1998 Oct;72(10):8309-15 [9733875.001]
  • [Cites] Virology. 1998 Sep 15;249(1):140-9 [9740785.001]
  • [Cites] Curr Clin Top Infect Dis. 1998;18:237-51 [9779358.001]
  • [Cites] Blood. 2006 Jan 1;107(1):277-84 [16150942.001]
  • [Cites] J Pathol. 2006 Jan;208(2):187-98 [16362980.001]
  • [Cites] EMBO Rep. 2006 Jan;7(1):114-9 [16311516.001]
  • [Cites] FASEB J. 2006 Jan;20(1):9-22 [16394262.001]
  • [Cites] Blood. 2006 Jan 15;107(2):725-32 [16160006.001]
  • [Cites] Annu Rev Med. 2006;57:1-18 [16409133.001]
  • [Cites] J Virol. 2006 Feb;80(3):1385-92 [16415016.001]
  • [Cites] J Immunol. 2006 Feb 1;176(3):1741-9 [16424204.001]
  • [Cites] Science. 2006 Feb 10;311(5762):856-61 [16469929.001]
  • [Cites] J Virol. 2006 Mar;80(5):2234-42 [16474131.001]
  • [Cites] J Virol. 2006 Mar;80(5):2243-56 [16474132.001]
  • [Cites] J Virol. 2006 Mar;80(5):2257-66 [16474133.001]
  • [Cites] J Virol. 2006 Mar;80(6):3062-70 [16501115.001]
  • [Cites] J Clin Invest. 2006 Mar;116(3):735-42 [16498502.001]
  • [Cites] J Gen Virol. 2006 Apr;87(Pt 4):795-802 [16528027.001]
  • [Cites] J Virol. 2006 Apr;80(7):3445-58 [16537612.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3051-61 [16540654.001]
  • [Cites] J Virol. 2006 Apr;80(8):4068-78 [16571823.001]
  • [Cites] Science. 2006 Mar 31;311(5769):1921-4 [16574866.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3658-66 [16585191.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3295-302 [16380446.001]
  • [Cites] Trends Microbiol. 2006 Apr;14(4):169-75 [16531046.001]
  • [Cites] RNA. 2006 May;12(5):733-50 [16540699.001]
  • [Cites] Wkly Epidemiol Rec. 2006 Jan 27;81(4):40 [16671237.001]
  • [Cites] J Clin Invest. 2006 May;116(5):1264-73 [16604194.001]
  • [Cites] J Virol. 2006 Jun;80(11):5251-60 [16699005.001]
  • [Cites] J Virol. 2006 Jun;80(11):5371-82 [16699017.001]
  • [Cites] Virology. 2006 May 10;348(2):309-27 [16546233.001]
  • [Cites] Virology. 2006 Jun 20;350(1):192-205 [16616289.001]
  • [Cites] Blood. 2006 Jul 1;108(1):141-51 [16543476.001]
  • [Cites] Int J Cancer. 2006 Sep 15;119(6):1262-7 [16615115.001]
  • [Cites] J Virol. 2005 Dec;79(24):15027-37 [16306573.001]
  • [Cites] J Biol Chem. 1999 Nov 5;274(45):31863-7 [10542211.001]
  • [Cites] AIDS. 1999 Oct 22;13(15):2105-11 [10546864.001]
  • [Cites] Virology. 1999 Oct 25;263(2):436-49 [10544116.001]
  • [Cites] J Natl Cancer Inst. 1999 Oct 20;91(20):1725-33 [10528022.001]
  • [Cites] Adv Cancer Res. 2000;77:1-24 [10549354.001]
  • [Cites] Hum Immunol. 1999 Oct;60(10):921-7 [10566591.001]
  • [Cites] Virology. 1999 Nov 25;264(2):254-64 [10562490.001]
  • [Cites] J Gen Virol. 1999 Nov;80 ( Pt 11):2889-900 [10580050.001]
  • [Cites] Eur Cytokine Netw. 1999 Dec;10(4):501-8 [10586116.001]
  • [Cites] Blood. 1999 Dec 15;94(12):4247-54 [10590069.001]
  • [Cites] N Engl J Med. 1998 Nov 5;339(19):1358-63 [9801396.001]
  • [Cites] Int J STD AIDS. 1998 Dec;9(12):751-5 [9874123.001]
  • [Cites] AIDS. 1998 Dec 24;12(18):2481-8 [9875587.001]
  • [Cites] Virology. 1998 Dec 20;252(2):304-12 [9878608.001]
  • [Cites] J Virol. 1999 Feb;73(2):1341-9 [9882339.001]
  • [Cites] Ann Biol Clin (Paris). 1999 Jan-Feb;57(1):19-28 [9920963.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Jan 1;20(1):34-8 [9928727.001]
  • [Cites] EMBO J. 1999 Feb 1;18(3):644-53 [9927424.001]
  • [Cites] EMBO J. 1999 Feb 1;18(3):654-63 [9927425.001]
  • [Cites] Crit Rev Oncog. 1998;9(2):107-24 [9973245.001]
  • [Cites] J Virol. 1999 Mar;73(3):2232-42 [9971806.001]
  • [Cites] Lab Invest. 1999 Feb;79(2):243-51 [10068212.001]
  • [Cites] Curr Opin Genet Dev. 1999 Feb;9(1):40-8 [10072350.001]
  • [Cites] Annu Rev Med. 1999;50:425-40 [10073287.001]
  • [Cites] J Virol. 1999 Apr;73(4):3040-53 [10074154.001]
  • [Cites] J Hum Virol. 1999 Jan-Feb;2(1):19-32 [10200596.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4546-51 [10200299.001]
  • [Cites] Virology. 1999 Apr 25;257(1):84-94 [10208923.001]
  • [Cites] Science. 1999 Apr 23;284(5414):641-4 [10213686.001]
  • [Cites] Leukemia. 1999 Apr;13 Suppl 1:S110-2 [10232382.001]
  • [Cites] J Virol. 2000 Jun;74(11):5300-9 [10799607.001]
  • [Cites] Blood. 2000 May 15;95(10):3032-43 [10807766.001]
  • [Cites] J Virol. 2000 Jul;74(13):6207-12 [10846108.001]
  • [Cites] Am J Pathol. 2000 Jun;156(6):1961-71 [10854219.001]
  • [Cites] Am J Pathol. 2000 Jun;156(6):2179-83 [10854238.001]
  • [Cites] J Med Virol. 2000 Jul;61(3):332-5 [10861641.001]
  • [Cites] Mol Pathol. 2000 Feb;53(1):43-7 [10884921.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8051-6 [10859362.001]
  • [Cites] J Biol Chem. 2000 Jul 21;275(29):21785-8 [10801897.001]
  • [Cites] Leukemia. 2000 Jul;14(7):1301-9 [10914556.001]
  • [Cites] J Gen Virol. 2000 Aug;81(Pt 8):2049-58 [10900044.001]
  • [Cites] J Immunol. 2000 Aug 15;165(4):2077-83 [10925292.001]
  • [Cites] J Virol. 2000 Sep;74(17):8194-201 [10933732.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):390-401 [10950365.001]
  • [Cites] J Virol. 2000 Sep;74(18):8532-40 [10954554.001]
  • [Cites] J Virol. 2000 Sep;74(18):8623-34 [10954564.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4873-80 [10987301.001]
  • [Cites] J Virol. 2000 Oct;74(20):9637-45 [11000236.001]
  • [Cites] J Virol. 2000 Oct;74(20):9646-54 [11000237.001]
  • [Cites] Blood. 2000 Oct 1;96(7):2537-42 [11001908.001]
  • [Cites] Immunity. 2000 Sep;13(3):365-74 [11021534.001]
  • [Cites] Nat Med. 2000 Oct;6(10):1121-7 [11017143.001]
  • [Cites] Mol Cell Biol. 2000 Nov;20(21):8254-63 [11027294.001]
  • [Cites] Adv Cancer Res. 2001;80:115-46 [11034542.001]
  • [Cites] J Gen Virol. 2000 Nov;81(Pt 11):2645-52 [11038375.001]
  • [Cites] Nat Cell Biol. 2000 Nov;2(11):819-25 [11056537.001]
  • [Cites] AIDS. 2000 Sep 29;14(14):2217-8 [11061672.001]
  • [Cites] Exp Cell Res. 2000 Nov 25;261(1):25-36 [11082272.001]
  • [Cites] J Gen Virol. 2000 Dec;81(Pt 12):3043-8 [11086135.001]
  • [Cites] J Virol. 2001 Jan;75(1):429-38 [11119611.001]
  • [Cites] J Virol. 2001 Jan;75(2):891-902 [11134302.001]
  • [Cites] J Virol. 2001 Feb;75(3):1378-86 [11152511.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Jan 1;124(1):16-9 [11165317.001]
  • [Cites] J Virol. 2001 Feb;75(4):1857-63 [11160684.001]
  • [Cites] J Virol. 2001 Feb;75(4):1864-9 [11160685.001]
  • [Cites] J Virol. 2001 Feb;75(4):1909-17 [11160690.001]
  • [Cites] J Virol. 2001 Mar;75(5):2345-52 [11160738.001]
  • [Cites] J Virol. 2001 Mar;75(5):2435-43 [11160746.001]
  • [Cites] J Virol. 2001 Mar;75(6):2866-78 [11222712.001]
  • [Cites] J Virol. 2001 Mar;75(6):2938-45 [11222719.001]
  • [Cites] Nat Rev Mol Cell Biol. 2000 Dec;1(3):187-98 [11252894.001]
  • [Cites] Science. 2001 Mar 16;291(5511):2150-5 [11251120.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):156-63 [16014885.001]
  • [Cites] J Virol. 2005 Aug;79(16):10308-29 [16051824.001]
  • [Cites] J Virol. 2005 Aug;79(16):10429-41 [16051835.001]
  • [Cites] J Virol. 2005 Sep;79(17):10952-67 [16103147.001]
  • [Cites] Trends Immunol. 2005 Sep;26(9):469-76 [16006187.001]
  • [Cites] J Clin Microbiol. 2005 Sep;43(9):4840-3 [16145154.001]
  • [Cites] J Virol. 2005 Oct;79(19):12173-84 [16160144.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2790-7 [15976177.001]
  • [Cites] Int J Epidemiol. 2005 Oct;34(5):1110-7 [16043440.001]
  • [Cites] Eur J Histochem. 2005 Jul-Sep;49(3):273-84 [16216813.001]
  • [Cites] AIDS Res Hum Retroviruses. 2005 Oct;21(10):869-75 [16225414.001]
  • [Cites] J Virol. 2005 Nov;79(21):13618-29 [16227282.001]
  • [Cites] J Virol. 2005 Nov;79(22):14371-82 [16254371.001]
  • [Cites] J Virol. 2005 Nov;79(22):14457-64 [16254382.001]
  • [Cites] Virology. 2005 Dec 5;343(1):47-64 [16154170.001]
  • [Cites] J Exp Med. 1998 Jul 6;188(1):193-8 [9653095.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Dec;2 Suppl 1:S4-11 [16341240.001]
  • [Cites] Cell Res. 2005 Nov-Dec;15(11-12):947-52 [16354573.001]
  • [Cites] Nature. 2005 Dec 15;438(7070):932-6 [16355210.001]
  • [Cites] Hum Pathol. 2006 Jan;37(1):23-31 [16360412.001]
  • [Cites] Traffic. 2001 Jun;2(6):375-84 [11389765.001]
  • [Cites] J Clin Invest. 2001 Jun;107(12):1599-606 [11413168.001]
  • [Cites] J Virol. 2006 Jan;80(2):697-709 [16378973.001]
  • [Cites] FEBS Lett. 2006 Jan 9;580(1):93-8 [16364321.001]
  • [Cites] Oncogene. 2001 Jun 7;20(26):3311-22 [11423981.001]
  • [Cites] Adv Cancer Res. 2001;81:125-59 [11430594.001]
  • [Cites] Adv Cancer Res. 2001;81:161-200 [11430595.001]
  • [Cites] J Virol. 2001 Aug;75(15):6894-900 [11435569.001]
  • [Cites] J Virol. 2001 Aug;75(15):7161-74 [11435597.001]
  • [Cites] J Hum Virol. 2001 Mar-Apr;4(2):62-73 [11437316.001]
  • [Cites] J Gen Virol. 2001 Aug;82(Pt 8):1965-70 [11458004.001]
  • [Cites] J Virol. 2001 Aug;75(16):7517-27 [11462024.001]
  • [Cites] J Virol. 2001 Aug;75(16):7572-82 [11462029.001]
  • [Cites] Biochim Biophys Acta. 2001 Jul 25;1540(1):1-21 [11476890.001]
  • [Cites] J Virol. 2001 Sep;75(17):7882-92 [11483733.001]
  • [Cites] J Biol Chem. 2001 Aug 17;276(33):31016-22 [11425857.001]
  • [Cites] J Virol. 2001 Sep;75(18):8660-73 [11507211.001]
  • [Cites] J Virol. 2001 Sep;75(18):8761-71 [11507221.001]
  • [Cites] J Biol Chem. 2001 Sep 7;276(36):33805-11 [11448967.001]
  • [Cites] J Virol. 2001 Oct;75(19):9509-16 [11533213.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3848-51 [11559722.001]
  • [Cites] J Virol. 2001 Nov;75(22):10933-40 [11602733.001]
  • [Cites] J Virol. 2001 Dec;75(23):11583-93 [11689640.001]
  • [Cites] J Virol. 2001 Dec;75(24):11961-73 [11711586.001]
  • [Cites] J Biol Chem. 2001 Dec 7;276(49):45979-87 [11590141.001]
  • [Cites] Mol Biol Cell. 2001 Dec;12(12):3987-99 [11739795.001]
  • [Cites] J Pathol. 2001 Dec;195(5):586-92 [11745695.001]
  • [Cites] Biotechniques. 2001 Dec;31(6):1286, 1288, 1290, passim [11768657.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3076-84 [11753987.001]
  • [Cites] J Gen Virol. 2002 Jan;83(Pt 1):179-88 [11752715.001]
  • [Cites] J Virol. 2002 Jan;76(2):802-16 [11752170.001]
  • [Cites] Blood. 2002 Jan 15;99(2):649-54 [11781250.001]
  • [Cites] Recent Results Cancer Res. 2002;159:27-37 [11785841.001]
  • [Cites] Am J Pathol. 2002 Jan;160(1):23-9 [11786394.001]
  • [Cites] J Virol. 2002 Feb;76(4):1744-52 [11799169.001]
  • [Cites] J Immunol. 2002 Feb 1;168(3):1226-34 [11801659.001]
  • [Cites] Front Biosci. 2002 Feb 1;7:d358-75 [11815281.001]
  • [Cites] J Virol. 2002 Mar;76(5):2440-8 [11836422.001]
  • [Cites] J Virol. 2002 Mar;76(5):2551-6 [11836434.001]
  • [Cites] Cell. 2002 Feb 8;108(3):407-19 [11853674.001]
  • [Cites] Int J Cancer. 2002 Feb 20;97(6):791-5 [11857356.001]
  • [Cites] J Leukoc Biol. 2002 Mar;71(3):445-57 [11867682.001]
  • [Cites] J Immunol. 2002 Mar 15;168(6):2634-43 [11884427.001]
  • [Cites] J Virol. 2002 Apr;76(7):3168-78 [11884541.001]
  • [Cites] J Virol. 2000 Jan;74(1):436-46 [10590133.001]
  • [Cites] J Exp Med. 1999 Dec 20;190(12):1857-68 [10601360.001]
  • [Cites] Virology. 2000 Jan 5;266(1):17-25 [10612656.001]
  • [Cites] Nature. 1999 Dec 23-30;402(6764):889-94 [10622254.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1151-7 [10666184.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1406-12 [10666218.001]
  • [Cites] J Exp Med. 2000 Feb 7;191(3):445-54 [10662790.001]
  • [Cites] J Virol. 2000 Mar;74(6):2867-75 [10684303.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):743-9 [10702388.001]
  • [Cites] J Virol. 2000 Apr;74(7):3388-98 [10708456.001]
  • [Cites] J Vasc Res. 2000 Jan-Feb;37(1):1-7 [10720880.001]
  • [Cites] J Virol. 2000 Apr;74(8):3659-67 [10729142.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Apr 2;270(1):23-7 [10733899.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):1180-9 [10741750.001]
  • [Cites] J Clin Virol. 2000 May;16(3):203-13 [10738139.001]
  • [Cites] Virology. 2000 Apr 10;269(2):335-44 [10753712.001]
  • [Cites] Mol Med. 1998 Jun;4(6):402-12 [10780883.001]
  • [Cites] J Immunol. 2000 May 1;164(9):4672-7 [10779772.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):729-36 [10793109.001]
  • [Cites] J Virol. 2000 Jun;74(11):5024-31 [10799576.001]
  • [Cites] Genes Dev. 2002 Aug 1;16(15):1977-89 [12154127.001]
  • [Cites] J Virol. 2002 Sep;76(17):8797-807 [12163600.001]
  • [Cites] J Infect Dis. 2000 Jun;181(6):1940-9 [10837173.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 Oct 1;22(2):209-10 [10843538.001]
  • [Cites] Cell Growth Differ. 2002 Aug;13(8):387-95 [12193477.001]
  • [Cites] J Med Virol. 2002 Nov;68(3):404-11 [12226829.001]
  • [Cites] Cancer Cell. 2002 Sep;2(3):229-41 [12242155.001]
  • [Cites] Nat Immunol. 2002 Oct;3(10):975-83 [12352970.001]
  • [Cites] Virology. 2002 Sep 30;301(2):293-304 [12359431.001]
  • [Cites] J Virol. 2002 Nov;76(22):11491-504 [12388711.001]
  • [Cites] J Virol. 2002 Nov;76(22):11596-604 [12388720.001]
  • [Cites] J Virol. 2002 Nov;76(22):11677-87 [12388727.001]
  • [Cites] J Virol. 2002 Dec;76(23):11880-8 [12414930.001]
  • [Cites] J Virol. 2002 Dec;76(23):12044-54 [12414946.001]
  • [Cites] J Pathol. 2002 Dec;198(4):511-6 [12434421.001]
  • [Cites] Science. 2002 Nov 15;298(5597):1432-5 [12434062.001]
  • [Cites] J Biol Chem. 2002 Nov 22;277(47):44765-71 [12235164.001]
  • [Cites] J Virol. 2002 Dec;76(24):12574-83 [12438583.001]
  • [Cites] J Virol. 2002 Dec;76(24):12917-24 [12438617.001]
  • [Cites] J Virol. 2003 Jan;77(1):592-9 [12477863.001]
  • [Cites] J Virol. 2003 Jan;77(1):600-23 [12477864.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):91-100 [12502931.001]
  • [Cites] J Virol. 2003 Jan;77(2):1524-39 [12502866.001]
  • [Cites] Annu Rev Med. 2003;54:285-303 [12525676.001]
  • [Cites] J Virol. 2003 Feb;77(4):2779-83 [12552022.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):1-3 [12556950.001]
  • [Cites] J Gen Virol. 2003 Feb;84(Pt 2):329-36 [12560564.001]
  • [Cites] J Virol. 2003 Mar;77(5):3131-47 [12584338.001]
  • [Cites] J Virol. 2003 Mar;77(6):3878-81 [12610165.001]
  • [Cites] Mol Cell Biol. 2003 Mar;23(6):2055-67 [12612078.001]
  • [Cites] Nat Med. 2003 Mar;9(3):300-6 [12592400.001]
  • [Cites] Cancer Cell. 2003 Feb;3(2):131-43 [12620408.001]
  • [Cites] J Virol. 2003 Apr;77(7):4205-20 [12634378.001]
  • [Cites] J Virol. 2003 Apr;77(7):4221-30 [12634379.001]
  • [Cites] J Biol Chem. 2003 Mar 14;278(11):9283-9 [12645526.001]
  • [Cites] J Gen Virol. 2003 May;84(Pt 5):1123-31 [12692277.001]
  • [Cites] J Virol. 2003 May;77(10):5975-84 [12719589.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2010-5 [12727810.001]
  • [Cites] J Virol. 2003 Jun;77(11):6188-96 [12743275.001]
  • [Cites] J Virol. 2003 Jun;77(11):6474-81 [12743304.001]
  • [Cites] Curr Drug Targets Infect Disord. 2003 Jun;3(2):129-35 [12769790.001]
  • [Cites] J Gen Virol. 2003 Jun;84(Pt 6):1485-91 [12771417.001]
  • [Cites] Oncogene. 2003 May 29;22(22):3371-85 [12776188.001]
  • [Cites] Microbiol Mol Biol Rev. 2003 Jun;67(2):175-212, table of contents [12794189.001]
  • [Cites] J Virol. 2001 Apr;75(8):3948-59 [11264383.001]
  • [Cites] J Virol. 2001 Apr;75(8):4008-13 [11264393.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4119-24 [11274437.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2641-8 [11289142.001]
  • [Cites] Blood. 2001 Apr 15;97(8):2374-80 [11290600.001]
  • [Cites] Virology. 2001 Apr 10;282(2):245-55 [11289807.001]
  • [Cites] J Biol Chem. 2001 Apr 20;276(16):13427-32 [11154704.001]
  • [Cites] Oncogene. 2001 Jan 25;20(4):523-30 [11313983.001]
  • [Cites] Oncogene. 2001 Feb 15;20(7):800-11 [11314014.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2001 Apr 29;356(1408):499-516 [11313008.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2001 Apr 29;356(1408):545-67 [11313011.001]
  • [Cites] Cytokine Growth Factor Rev. 2001 Jun-Sep;12(2-3):245-57 [11325605.001]
  • [Cites] Mol Cell. 2001 Apr;7(4):833-43 [11336706.001]
  • [Cites] Blood. 2001 May 15;97(10):3244-50 [11342455.001]
  • [Cites] J Virol. 2001 Jun;75(12):5614-26 [11356969.001]
  • [Cites] Arch Pathol Lab Med. 2001 Jun;125(6):785-9 [11371231.001]
  • [Cites] Virology. 2001 Jun 5;284(2):235-49 [11384223.001]
  • [Cites] J Dermatol Sci. 2001 Jul;26(3):182-93 [11390203.001]
  • [Cites] J Virol. 2001 Jul;75(13):6193-8 [11390621.001]
  • [Cites] J Virol. 2001 Jul;75(13):6245-8 [11390631.001]
  • [Cites] J Virol. 2004 Jan;78(1):294-301 [14671111.001]
  • [Cites] Blood. 2004 Jan 1;103(1):222-8 [12969971.001]
  • [Cites] J Immunol. 2001 Jul 1;167(1):505-13 [11418689.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1251-69 [11423257.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):72-84 [14729610.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] Herpes. 2003 Dec;10(3):72-7 [14759339.001]
  • [Cites] Virology. 2004 Jan 20;318(2):542-55 [14972523.001]
  • [Cites] Virology. 2004 Feb 20;319(2):225-36 [14980483.001]
  • [Cites] FASEB J. 2004 Mar;18(3):422-7 [15003988.001]
  • [Cites] J Virol. 2004 Apr;78(7):3601-20 [15016882.001]
  • [Cites] Ann N Y Acad Sci. 2003 Dec;1010:237-48 [15033728.001]
  • [Cites] J Virol. 2004 Apr;78(8):4207-23 [15047836.001]
  • [Cites] J Virol. 2004 Apr;78(8):4248-67 [15047839.001]
  • [Cites] J Med Primatol. 2004 Feb;33(1):1-9 [15061726.001]
  • [Cites] J Exp Med. 2004 Apr 5;199(7):993-1003 [15067035.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4821-6 [15047889.001]
  • [Cites] J Biol Chem. 2004 Apr 16;279(16):16822-31 [14742422.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2774-81 [15087393.001]
  • [Cites] Blood. 2004 May 1;103(9):3465-73 [14726403.001]
  • [Cites] J Virol. 2004 May;78(10):5491-9 [15113928.001]
  • [Cites] J Virol. 2004 Jun;78(12):6389-98 [15163732.001]
  • [Cites] J Virol. 2004 Jun;78(12):6585-94 [15163750.001]
  • [Cites] J Gen Virol. 2004 Jun;85(Pt 6):1347-61 [15166416.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4064-8 [15205312.001]
  • [Cites] J Biol Chem. 2004 Jun 25;279(26):27088-97 [15102829.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9399-404 [15190178.001]
  • [Cites] J Virol. 2004 Jul;78(14):7299-310 [15220403.001]
  • [Cites] Nat Genet. 2004 Jul;36(7):687-93 [15220918.001]
  • [Cites] Front Biosci. 1997 Mar 1;2:d126-46 [9159220.001]
  • [Cites] Blood. 2004 Aug 1;104(3):810-4 [15073028.001]
  • [Cites] Oncogene. 2004 Jul 29;23(34):5770-80 [15235582.001]
  • [Cites] Virus Genes. 2004 Oct;29(2):175-82 [15284477.001]
  • [Cites] Semin Cancer Biol. 2004 Oct;14(5):387-96 [15288264.001]
  • [Cites] J Virol. 2004 Sep;78(17):9336-42 [15308728.001]
  • [Cites] J Interferon Cytokine Res. 2004 Aug;24(8):439-54 [15320958.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2004 Sep;45(9):2906-14 [15326101.001]
  • [Cites] J Virol. 2004 Sep;78(18):10187-92 [15331751.001]
  • [Cites] Front Biosci. 2004 Sep 1;9:2245-72 [15353285.001]
  • [Cites] J Virol. 2004 Oct;78(19):10348-59 [15367601.001]
  • [Cites] Virology. 2004 Oct 10;328(1):7-18 [15380353.001]
  • [Cites] J Med Virol. 2004 Nov;74(3):390-6 [15368522.001]
  • [Cites] J Virol. 2004 Oct;78(20):11108-20 [15452231.001]
  • [Cites] J Virol. 2004 Oct;78(20):11121-9 [15452232.001]
  • [Cites] J Virol. 2002 Apr;76(7):3421-39 [11884567.001]
  • [Cites] J Biol Chem. 2002 Apr 5;277(14):12023-31 [11821384.001]
  • [Cites] J Virol. 2002 May;76(9):4390-400 [11932406.001]
  • [Cites] Biol Chem. 2002 Feb;383(2):255-61 [11934263.001]
  • [Cites] J Biol Chem. 2002 Apr 19;277(16):13745-51 [11830587.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5573-8 [11943871.001]
  • [Cites] J Biol Chem. 2002 Apr 26;277(17):14547-56 [11832484.001]
  • [Cites] J Virol. 2002 May;76(10):4688-98 [11967286.001]
  • [Cites] J Virol. 2002 May;76(10):5000-13 [11967316.001]
  • [Cites] AIDS. 2002 May 24;16(8):F9-18 [12004288.001]
  • [Cites] DNA Cell Biol. 2002 Mar;21(3):151-62 [12015894.001]
  • [Cites] J Virol. 2002 Jun;76(12):6185-96 [12021352.001]
  • [Cites] EMBO J. 2002 Jun 3;21(11):2602-15 [12032073.001]
  • [Cites] Lancet Infect Dis. 2002 May;2(5):281-92 [12062994.001]
  • [Cites] J Gen Virol. 2002 Jul;83(Pt 7):1535-45 [12075072.001]
  • [Cites] Clin Microbiol Rev. 2002 Jul;15(3):439-64 [12097251.001]
  • [Cites] Blood. 2002 Aug 1;100(3):888-96 [12130499.001]
  • [Cites] Virology. 2002 Jul 5;298(2):181-8 [12127781.001]
  • [Cites] J Cutan Pathol. 2002 Feb;29(2):72-8 [12150136.001]
  • [Cites] Hum Pathol. 2002 Jun;33(6):652-9 [12152166.001]
  • [Cites] Science. 1993 Feb 12;259(5097):971-4 [8438157.001]
  • [Cites] Medicine (Baltimore). 1993 Jul;72(4):245-61 [8341141.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10683-8 [12145325.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1919-21 [12176919.001]
  • [Cites] Arch Dermatol. 1993 Oct;129(10):1291-6 [7692824.001]
  • [Cites] J Virol. 1994 Mar;68(3):1886-902 [8107249.001]
  • [Cites] Cancer Lett. 1994 Aug 15;83(1-2):191-6 [8062214.001]
  • [Cites] Blood. 1994 Oct 15;84(8):2711-20 [7522639.001]
  • [Cites] Cell. 1994 Oct 7;79(1):119-30 [7923370.001]
  • [Cites] J Pathol. 1994 May;173(1):23-31 [7523640.001]
  • [Cites] Int Immunol. 1994 Aug;6(8):1125-31 [7526889.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Res Virol. 1994 May-Aug;145(3-4):251-9 [7528440.001]
  • [Cites] Science. 1995 Feb 24;267(5201):1078-9 [7855583.001]
  • [Cites] Lancet. 1995 Mar 25;345(8952):761-2 [7891488.001]
  • [Cites] J Immunol. 1995 Apr 1;154(7):3582-92 [7897237.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1181-5 [7700310.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1043-4 [7723505.001]
  • [Cites] Lancet. 1995 May 6;345(8958):1180 [7723569.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] Nature. 1995 Aug 17;376(6541):596-9 [7637809.001]
  • [Cites] N Engl J Med. 1995 Sep 21;333(12):798; author reply 798-9 [7643891.001]
  • [Cites] J Cell Sci. 1995 Jun;108 ( Pt 6):2511-23 [7673365.001]
  • [Cites] Gene Ther. 1994 May;1(3):208-16 [7584083.001]
  • [Cites] Nat Med. 1995 Jul;1(7):707-8 [7585156.001]
  • [Cites] J Emerg Med. 1995 Sep-Oct;13(5):671-4 [8530789.001]
  • [Cites] Nat Med. 1995 Dec;1(12):1274-8 [7489408.001]
  • [Cites] J Virol. 1996 Jan;70(1):549-58 [8523568.001]
  • [Cites] Arch Intern Med. 1996 Jan 22;156(2):202-4 [8546554.001]
  • [Cites] J Natl Cancer Inst. 1996 Apr 3;88(7):450-5 [8618237.001]
  • [Cites] EMBO J. 1996 Feb 15;15(4):799-809 [8631301.001]
  • [Cites] J Infect Dis. 1996 Mar;173(3):542-9 [8627015.001]
  • [Cites] Nat Med. 1996 Mar;2(3):342-6 [8612236.001]
  • [Cites] N Engl J Med. 1996 Jul 25;335(4):233-41 [8657239.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6641-6 [8692871.001]
  • [Cites] Leukemia. 1996 Jul;10(7):1237-40 [8684008.001]
  • [Cites] Annu Rev Immunol. 1996;14:649-83 [8717528.001]
  • [Cites] Nature. 1996 Aug 1;382(6590):410 [8684480.001]
  • [Cites] Nat Med. 1996 Aug;2(8):918-24 [8705863.001]
  • [Cites] Nat Med. 1996 Aug;2(8):925-8 [8705864.001]
  • [Cites] Nature. 1996 Aug 29;382(6594):816-8 [8752276.001]
  • [Cites] Clin Infect Dis. 1996 Jun;22(6):1120-1 [8783733.001]
  • [Cites] AIDS. 1996 Feb;10(2):175-80 [8838705.001]
  • [Cites] J Virol. 2003 Jul;77(14):7978-90 [12829837.001]
  • [Cites] J Virol. 2003 Jul;77(14):8019-30 [12829841.001]
  • [Cites] J Virol. 2003 Jul;77(14):8147-52 [12829853.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8490-5 [12832621.001]
  • [Cites] Clin Infect Dis. 2003 Jul 15;37(2):285-91 [12856221.001]
  • [Cites] J Virol. 2003 Aug;77(15):8532-40 [12857922.001]
  • [Cites] Intervirology. 2003;46(3):141-9 [12867751.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5150-63 [12910252.001]
  • [Cites] J Virol. 2003 Sep;77(17):9346-58 [12915550.001]
  • [Cites] J Virol. 2003 Sep;77(17):9399-411 [12915555.001]
  • [Cites] J Virol. 2003 Sep;77(17):9451-62 [12915560.001]
  • [Cites] J Cell Sci. 2003 Sep 15;116(Pt 18):3721-8 [12890756.001]
  • [Cites] J Virol. 2003 Sep;77(18):9738-49 [12941882.001]
  • [Cites] J Virol. 2003 Sep;77(18):9758-68 [12941884.001]
  • [Cites] J Virol. 2003 Oct;77(19):10179-85 [12970403.001]
  • [Cites] APMIS. 2003 Jul-Aug;111(7-8):698-714 [12974773.001]
  • [Cites] N Engl J Med. 2003 Sep 18;349(12):1113-22 [13679525.001]
  • [Cites] J Virol. 2003 Nov;77(21):11425-35 [14557628.001]
  • [Cites] Mol Cell Biol. 2003 Nov;23(22):8282-94 [14585985.001]
  • [Cites] J Leukoc Biol. 2003 Nov;74(5):757-63 [12960240.001]
  • [Cites] Cell. 1996 Oct 4;87(1):13-20 [8858144.001]
  • [Cites] AIDS. 1996 Sep;10(10):1101-5 [8874626.001]
  • [Cites] J Biol Chem. 2003 Dec 26;278(52):52437-45 [14563855.001]
  • [Cites] Oncogene. 2004 Jan 15;23(2):514-23 [14724579.001]
  • [Cites] Lancet. 1996 Oct 26;348(9035):1133-8 [8888167.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1739-44 [8939871.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14862-7 [8962146.001]
  • [Cites] N Engl J Med. 1997 Jan 16;336(3):163-71 [8988896.001]
  • [Cites] J Virol. 1997 Jan;71(1):314-24 [8985352.001]
  • [Cites] J Virol. 1997 Jan;71(1):715-9 [8985403.001]
  • [Cites] Nature. 1997 Jan 23;385(6614):347-50 [9002520.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):690-4 [9012846.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Feb 4;94(3):979-84 [9023368.001]
  • [Cites] J Virol. 1997 Mar;71(3):1984-91 [9032330.001]
  • [Cites] Lancet. 1997 Feb 15;349(9050):490-5 [9040590.001]
  • [Cites] Nat Med. 1997 Mar;3(3):287-92 [9055855.001]
  • [Cites] Nat Med. 1997 Mar;3(3):293-8 [9055856.001]
  • [Cites] Lancet. 1997 Mar 15;349(9054):774-5 [9074581.001]
  • [Cites] J Virol. 1997 May;71(5):4138-44 [9094697.001]
  • [Cites] J Infect Dis. 1997 May;175(5):1193-7 [9129084.001]
  • [Cites] AIDS. 1997 May;11(6):713-21 [9143602.001]
  • [Cites] J Virol. 1997 Jun;71(6):4193-8 [9151805.001]
  • [Cites] Hum Pathol. 1997 Jun;28(6):748-50 [9191012.001]
  • [Cites] Br J Haematol. 1997 Jun;97(3):515-22 [9207392.001]
  • [Cites] Lymphology. 1997 Jun;30(2):63-76 [9215976.001]
  • [Cites] J Virol. 1997 Aug;71(8):5915-21 [9223481.001]
  • [Cites] J Biol Chem. 1997 Aug 1;272(31):19625-31 [9235971.001]
  • [Cites] Science. 1997 Sep 12;277(5332):1656-9 [9287217.001]
  • [Cites] AIDS. 1997 Sep;11(11):1333-40 [9302442.001]
  • [Cites] Blood. 1997 Oct 1;90(7):2826-9 [9326251.001]
  • [Cites] Science. 1997 Oct 10;278(5336):290-4 [9323208.001]
  • [Cites] J Pathol. 1997 Jul;182(3):262-5 [9349227.001]
  • [Cites] Oncogene. 1997 Oct 16;15(16):1979-85 [9365244.001]
  • [Cites] Nature. 1997 Nov 13;390(6656):184-7 [9367157.001]
  • [Cites] Virology. 1997 Nov 10;238(1):22-9 [9375005.001]
  • [Cites] Int J Cancer. 1997 Nov 14;73(4):562-9 [9389573.001]
  • [Cites] J Virol. 1998 Jan;72(1):701-7 [9420276.001]
  • [Cites] Nature. 1998 Jan 1;391(6662):86-9 [9422510.001]
  • [Cites] J Virol. 1998 Feb;72(2):1005-12 [9444993.001]
  • [Cites] Blood. 1998 Mar 1;91(5):1671-9 [9473233.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3537-42 [9520401.001]
  • [Cites] Nat Med. 1998 Apr;4(4):435-40 [9546789.001]
  • [Cites] J Virol. 1998 Jun;72(6):4980-8 [9573267.001]
  • [Cites] J Virol. 1998 Jun;72(6):5182-8 [9573290.001]
  • [Cites] J Virol. 1998 Jul;72(7):5433-40 [9620998.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] J Virol. 2004 Nov;78(21):11926-38 [15479833.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2903-11 [15231571.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2736-8 [15238422.001]
  • [Cites] J Virol. 2004 Nov;78(22):12566-75 [15507644.001]
  • [Cites] J Natl Cancer Inst. 1972 Dec;49(6):1509-26 [4647841.001]
  • [Cites] Am J Dermatopathol. 1981 Summer;3(2):111-4 [7270808.001]
  • [Cites] Lancet. 1981 Sep 19;2(8247):598-600 [6116083.001]
  • [Cites] J Am Acad Dermatol. 1981 Oct;5(4):468-71 [7287964.001]
  • [Cites] N Engl J Med. 1981 Dec 10;305(24):1439-44 [6272110.001]
  • [Cites] Ariz Med. 1981 Dec;38(12):902-4 [7332494.001]
  • [Cites] JAMA. 1986 Jul 4;256(1):20-1, 24-5 [3012133.001]
  • [Cites] Cancer Res. 1986 Dec;46(12 Pt 1):6333-8 [3022918.001]
  • [Cites] Cell. 1989 Aug 25;58(4):729-39 [2475256.001]
  • [Cites] Lancet. 1990 Jan 20;335(8682):123-8 [1967430.001]
  • [Cites] Mol Cell Biol. 1990 Jun;10(6):2448-57 [2342456.001]
  • [Cites] Cell. 1991 Sep 20;66(6):1071-4 [1833062.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Mar 31;183(3):1167-74 [1567395.001]
  • [Cites] Cancer Surv. 1991;10:5-22 [1821323.001]
  • [Cites] J Biol Chem. 1992 Dec 15;267(35):25589-96 [1460054.001]
  • [Cites] Gene Expr. 1992;2(4):329-37 [1472868.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):528-37 [8342600.001]
  • [Cites] Mol Cell Biol. 1993 Oct;13(10):6501-8 [8413249.001]
  • (PMID = 17672038.001).
  • [ISSN] 0927-3042
  • [Journal-full-title] Cancer treatment and research
  • [ISO-abbreviation] Cancer Treat. Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA096512; United States / NCI NIH HHS / CA / R01 CA124332-03; United States / NCI NIH HHS / CA / R01 CA096512-02; United States / NIDCR NIH HHS / DE / R01 DE017333-03; United States / NCI NIH HHS / CA / R01 CA096512-03; United States / NIDCR NIH HHS / DE / DE017333-02; United States / NCI NIH HHS / CA / R01 CA124332; United States / NCI NIH HHS / CA / CA096512-01A2; United States / NIDCR NIH HHS / DE / R01 DE017333-02; United States / NCI NIH HHS / CA / R01 CA096512-05; United States / NCI NIH HHS / CA / R01 CA132637-02; United States / NIDCR NIH HHS / DE / DE017333-01; United States / NCI NIH HHS / CA / CA096512-02; United States / NIDCR NIH HHS / DE / DE017333-03; United States / NIDCR NIH HHS / DE / R01 DE017333; United States / NCI NIH HHS / CA / R01 CA096512-01A2; United States / NCI NIH HHS / CA / R01 CA096512-04; United States / NIDCR NIH HHS / DE / R01 DE017333-01; United States / NCI NIH HHS / CA / R01 CA132637; United States / NCI NIH HHS / CA / R01 CA132637-01A1; United States / NCI NIH HHS / CA / R01 CA124332-02
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 504
  • [Other-IDs] NLM/ NIHMS165766; NLM/ PMC2798888
  •  go-up   go-down


77. Ohtawa M, Ichikawa S, Teishikata Y, Fujimuro M, Yokosawa H, Matsuda A: 9-(2-C-Cyano-2-deoxy-beta-D-arabino-pentofuranosyl)guanine, a potential antitumor agent against B-lymphoma infected with Kaposi's sarcoma-associated herpesvirus. J Med Chem; 2007 May 3;50(9):2007-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Several 9-(2-C-cyano-2-deoxy-l-beta-d-arabino-pentofuranosyl)purine derivatives were tested against Kaposi's sarcoma-associated herpesvirus (KSHV)-infected primary effusion lymphoma (PEL) cells.
  • Therefore, it was found that compounds 3, 4, 5, and 6 showed selective cytotoxicity against PEL cells infected with KSHV.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17402726.001).
  • [ISSN] 0022-2623
  • [Journal-full-title] Journal of medicinal chemistry
  • [ISO-abbreviation] J. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 9-(2-C-cyano-2-deoxy-arabino-pentofuranosyl)guanine; 0 / Antineoplastic Agents; 0 / Arabinonucleosides; 12133JR80S / Guanosine; 63231-63-0 / RNA; 9007-49-2 / DNA
  •  go-up   go-down


78. Maeder M, Spieler P, Krapf R, Diethelm M: Cytologically malignant lymphoid pericardial effusion with benign clinical outcome. Swiss Med Wkly; 2005 Jun 25;135(25-26):377-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologically malignant lymphoid pericardial effusion with benign clinical outcome.
  • BACKGROUND: Isolated malignant pericardial effusion is a manifestation of primary cardiac lymphoma (PCL) and primary effusion lymphoma (PEL), rare types of non-Hodgkin's lymphoma (NHL).
  • The diagnosis is based on different cytological methods and analyses including DNA-image cytometry (ICM-DNA).
  • CONCLUSIONS: Despite the highly atypical cytomorphology including unequivocal DNA aneuploidy, long-term survival in both patients strongly suggests that pronounced reactive lymphocytic changes are probably due to viral pericarditis rather than PCL or PEL as underlying conditions.
  • It seems that DNA-aneuploidy may be not absolutely specific for the detection of malignant lymphoid cells in pericardial fluid.
  • [MeSH-major] Heart Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Pericardial Effusion / diagnosis

  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16106328.001).
  • [ISSN] 1424-7860
  • [Journal-full-title] Swiss medical weekly
  • [ISO-abbreviation] Swiss Med Wkly
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


79. Boulanger E, Meignin V, Afonso PV, Duprez R, Oksenhendler E, Agbalika F, Gessain A: Extracavitary tumor after primary effusion lymphoma: relapse or second distinct lymphoma? Haematologica; 2007 Sep;92(9):1275-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HHV-8-associated solid lymphomas which develop in extracavitary sites during the course of primary effusion lymphoma (PEL) could represent the relapse of original PEL tumors in different anatomical sites, or newly occurring distinct HHV-8-associated lymphomas, such as multicentric Castleman disease-related microlymphomas.
  • [MeSH-major] Herpesviridae Infections / complications. Herpesvirus 8, Human / isolation & purification. Lymphoma / complications. Lymphoma, AIDS-Related / complications. Neoplasm Recurrence, Local / complications. Pleural Effusion, Malignant / complications

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17768127.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


80. Meeker JD, Susi P, Flynn MR: Hexavalent chromium exposure and control in welding tasks. J Occup Environ Hyg; 2010 Nov;7(11):607-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hexavalent chromium exposure and control in welding tasks.
  • Studies of exposure to the lung carcinogen hexavalent chromium (CrVI) from welding tasks are limited, especially within the construction industry where overexposure may be common.
  • In addition, despite the OSHA requirement that the use of engineering controls such as local exhaust ventilation (LEV) first be considered before relying on other strategies to reduce worker exposure to CrVI, data on the effectiveness of LEV to reduce CrVI exposures from welding are lacking.
  • (3) field survey data of construction welders collected by the Center for Construction Research and Training (CPWR); and (4) controlled welding trials conducted by CPWR to assess the effectiveness of a portable LEV unit to reduce CrVI exposure.
  • In the OSHA (n = 181) and TWI (n = 124) datasets, which included very few samples from the construction industry, the OSHA permissible exposure level (PEL) for CrVI (5 μg/m(3)) was exceeded in 9% and 13% of samples, respectively.
  • CrVI concentrations measured in the CPWR field surveys (n = 43) were considerably higher, and 25% of samples exceeded the PEL.
  • Only weak-to-moderate correlations were found between total particulate matter and CrVI, suggesting that total particulate matter concentrations are not a good surrogate for CrVI exposure in retrospective studies.
  • However, exposure could be substantially reduced with proper use of LEV.
  • [MeSH-major] Air Pollutants, Occupational. Chromium. Occupational Exposure / prevention & control. Occupational Exposure / statistics & numerical data. Welding / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHROMIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20845207.001).
  • [ISSN] 1545-9632
  • [Journal-full-title] Journal of occupational and environmental hygiene
  • [ISO-abbreviation] J Occup Environ Hyg
  • [Language] eng
  • [Grant] United States / PHS HHS / / 0H008307
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Air Pollutants, Occupational; 0 / Particulate Matter; 0R0008Q3JB / Chromium; 12597-68-1 / Stainless Steel; 18540-29-9 / chromium hexavalent ion
  •  go-up   go-down


81. Zhuge B, Du GC, Shen W, Zhuge J, Chen J: Efficient secretory expression of an alkaline pectate lyase gene from Bacillus subtilis in E. coli and the purification and characterization of the protein. Biotechnol Lett; 2007 Mar;29(3):405-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficient secretory expression of an alkaline pectate lyase gene from Bacillus subtilis in E. coli and the purification and characterization of the protein.
  • The gene encoding pectate lyase (PL) from Bacillus subtilis WSHB04-02 was amplified by PCR, fused with a periplasmic secretion signal peptide sequence, pelB, from pET22b(+), cloned and expressed in Escherichia coli cells using a temperature control vector, pHsh.
  • [MeSH-minor] Enzyme Activation. Enzyme Stability. Gene Expression Regulation, Bacterial / physiology. Gene Expression Regulation, Enzymologic / physiology. Genetic Enhancement / methods. Recombinant Proteins / biosynthesis. Recombinant Proteins / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17237974.001).
  • [ISSN] 1573-6776
  • [Journal-full-title] Biotechnology letters
  • [ISO-abbreviation] Biotechnol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Recombinant Proteins; EC 4.2.2.- / Polysaccharide-Lyases; EC 4.2.2.2 / pectate lyase
  •  go-up   go-down


82. Nemunaitis MC, Schussler JM, Shiller SM, Sloan LM, Mennel RG: Primary effusion lymphoma diagnosed by pericardiocentesis. Proc (Bayl Univ Med Cent); 2009 Jan;22(1):77-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL), formerly known as body cavity-based lymphoma, is a high-grade B-cell non-Hodgkin's lymphoma associated with Kaposi's sarcoma and human herpesvirus 8 infection.
  • PEL is often diagnosed in patients with HIV infection and carries a poor prognosis, with median survival near 6 months.
  • We describe a patient who presented with symptomatic pericardial effusion, secondary to newly diagnosed PEL, and no prior history of HIV infection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Oncol. 2005 Sep;17(5):447-55 [16093794.001]
  • [Cites] Ann Hematol. 2005 Aug;84(8):551-2 [15800785.001]
  • [Cites] J Clin Oncol. 2005 Jul 1;23(19):4372-80 [15994147.001]
  • [Cites] Cancer Biol Ther. 2005 Jan;4(1):77-82 [15662128.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):3102-8 [15837766.001]
  • [Cites] Leukemia. 2005 Mar;19(3):473-6 [15674353.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2510-8 [15572586.001]
  • [Cites] Leukemia. 1999 May;13(5):664-70 [10374868.001]
  • [Cites] Am J Hematol. 1998 Mar;57(3):266 [9495391.001]
  • [Cites] Blood. 1997 Dec 15;90(12):4894-900 [9389706.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Blood. 1989 Feb 15;73(3):792-9 [2537119.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1985 Jun 28;34(25):373-5 [2989677.001]
  • [Cites] Clin Pharmacol Ther. 1978 Jan;23(1):68-72 [618710.001]
  • [Cites] Leukemia. 2004 Oct;18(10):1699-704 [15343345.001]
  • [Cites] AIDS Patient Care STDS. 2004 Feb;18(2):67-73 [15006181.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3948-54 [14581418.001]
  • [Cites] Leuk Lymphoma. 2001 Apr;41(3-4):439-43 [11378560.001]
  • [Cites] JAMA. 2001 Apr 11;285(14):1880-5 [11308402.001]
  • [Cites] Blood. 2001 Feb 1;97(3):744-51 [11157493.001]
  • [Cites] AIDS. 2001 Jan 26;15(2):280-2 [11216942.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):729-36 [10793109.001]
  • [Cites] Cancer. 2007 Aug 25;111(4):224-33 [17554754.001]
  • [Cites] Leukemia. 2007 Aug;21(8):1792-801 [17568816.001]
  • [Cites] Oncologist. 2007 May;12(5):569-76 [17522245.001]
  • [Cites] J Cardiol. 2007 Apr;49(4):205-10 [17460882.001]
  • [Cites] Ann Oncol. 2006 Dec;17(12):1849-50 [16766593.001]
  • [Cites] Int J Hematol. 2006 May;83(4):328-30 [16757433.001]
  • [Cites] Blood. 2006 Jan 1;107(1):13-20 [16099881.001]
  • (PMID = 19169406.001).
  • [ISSN] 0899-8280
  • [Journal-full-title] Proceedings (Baylor University. Medical Center)
  • [ISO-abbreviation] Proc (Bayl Univ Med Cent)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2626366
  •  go-up   go-down


83. Bakare AA, Pandey AK, Bajpayee M, Bhargav D, Chowdhuri DK, Singh KP, Murthy RC, Dhawan A: DNA damage induced in human peripheral blood lymphocytes by industrial solid waste and municipal sludge leachates. Environ Mol Mutagen; 2007 Jan;48(1):30-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA damage induced in human peripheral blood lymphocytes by industrial solid waste and municipal sludge leachates.
  • Exposure of humans to toxic compounds occurs mostly in the form of complex mixtures.
  • In the present study, leachates of solid wastes from a polyfiber factory (PFL), an aeronautical plant (AEL), and a municipal sludge leachate (MSL) were assessed for their ability to induce DNA damage in human peripheral blood lymphocytes using the alkaline Comet assay.
  • Lymphocytes were incubated with 0.5-15.0% concentrations (pH range 7.1-7.4) of the test leachates for 3 hr at 37 degrees C, and treatment with 1 mM ethyl methanesulfonate served as a positive control.
  • Our data indicate that the ever-increasing amounts of leachates from waste landfill sites have the potential to induce DNA damage and suggest that the exposure of human populations to these leachates may lead to adverse health effects.
  • [MeSH-major] Industrial Waste. Lymphocytes / drug effects. Water Pollutants, Chemical / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17163505.001).
  • [ISSN] 0893-6692
  • [Journal-full-title] Environmental and molecular mutagenesis
  • [ISO-abbreviation] Environ. Mol. Mutagen.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Industrial Waste; 0 / Metals, Heavy; 0 / Water Pollutants, Chemical
  •  go-up   go-down


84. Deloose ST, Smit LA, Pals FT, Kersten MJ, van Noesel CJ, Pals ST: High incidence of Kaposi sarcoma-associated herpesvirus infection in HIV-related solid immunoblastic/plasmablastic diffuse large B-cell lymphoma. Leukemia; 2005 May;19(5):851-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposi sarcoma-associated herpesvirus (KSHV) is known to be associated with two distinct lymphoproliferative disorders: primary effusion lymphoma (PEL) and multicentric Castleman disease (MCD)/MCD-associated plasmablastic lymphoma.
  • Our results indicate that KSHV infection is not restricted to PEL and MCD; it is also common (38%) in HIV-related solid immunoblastic/plasmablastic lymphomas.


85. Lefort S, Flamand L: Kaposi's sarcoma-associated herpesvirus K-bZIP protein is necessary for lytic viral gene expression, DNA replication, and virion production in primary effusion lymphoma cell lines. J Virol; 2009 Jun;83(11):5869-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kaposi's sarcoma-associated herpesvirus K-bZIP protein is necessary for lytic viral gene expression, DNA replication, and virion production in primary effusion lymphoma cell lines.
  • Kaposi's sarcoma-associated herpesvirus (KSHV) is the causative agent of three human proliferative disorders, namely, Kaposi's sarcoma, primary effusion lymphomas (PEL), and multicentric Castleman's disease.
  • To evaluate the physiological roles of K-bZIP in the context of PEL, we generated BCBL-1 cells with a tetracycline (Tet)-inducible small hairpin RNA (shRNA) directed against the K8 mRNA to knock down K-bZIP expression at different points during KSHV's life cycle.
  • Similar effects were seen at the protein level for RTA (immediate-early protein) and K8.1 (late protein) expression.
  • Interestingly, a direct correlation between K-bZIP levels and viral lytic mRNAs was noticed.
  • The same effects were observed following knockdown of K-bZIP in another PEL cell line, BC3.
  • Finally, using shRNA-K8-inducible 293 cells, we report that de novo synthesis of K-bZIP is not necessary for initiation of infection and latency establishment.
  • These data support the concept that K-bZIP is essential for lytic viral gene expression, viral DNA replication, and virus propagation in PEL cells.
  • [MeSH-major] Basic-Leucine Zipper Transcription Factors / metabolism. DNA Replication / genetics. Gene Expression Regulation, Viral / genetics. Herpesvirus 8, Human / metabolism. Lymphoma, Primary Effusion / virology. Repressor Proteins / metabolism. Viral Proteins / metabolism. Virion / growth & development. Virus Assembly

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] J Virol. 1995 May;69(5):2998-3006 [7707526.001]
  • [Cites] Nat Med. 1996 Mar;2(3):342-6 [8612236.001]
  • [Cites] N Engl J Med. 1996 May 16;334(20):1292-7 [8609946.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2648-54 [8839859.001]
  • [Cites] J Virol. 1996 Dec;70(12):8340-7 [8970953.001]
  • [Cites] J Virol. 1997 Jan;71(1):314-24 [8985352.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10866-71 [9724796.001]
  • [Cites] J Virol. 1999 Mar;73(3):1909-17 [9971770.001]
  • [Cites] J Virol. 1999 Mar;73(3):2232-42 [9971806.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4546-51 [10200299.001]
  • [Cites] J Virol. 1999 Nov;73(11):9348-61 [10516043.001]
  • [Cites] J Virol. 2005 Mar;79(6):3479-87 [15731242.001]
  • [Cites] J Virol. 2005 Apr;79(8):4952-64 [15795281.001]
  • [Cites] J Virol. 2005 Aug;79(15):9912-25 [16014952.001]
  • [Cites] J Virol. 2006 Dec;80(24):12171-86 [17020951.001]
  • [Cites] J Virol. 2007 Oct;81(20):10950-60 [17652396.001]
  • [Cites] J Virol. 2007 Dec;81(24):13519-32 [17913803.001]
  • [Cites] J Virol. 2000 Jul;74(13):6207-12 [10846108.001]
  • [Cites] J Virol. 2000 Dec;74(24):11977-82 [11090200.001]
  • [Cites] J Virol. 2001 Feb;75(3):1487-506 [11152521.001]
  • [Cites] J Gen Virol. 2001 Mar;82(Pt 3):507-12 [11172091.001]
  • [Cites] J Virol. 2001 Aug;75(15):6786-99 [11435557.001]
  • [Cites] J Virol. 2001 Oct;75(19):9509-16 [11533213.001]
  • [Cites] J Virol. 2003 Jan;77(2):1441-51 [12502859.001]
  • [Cites] J Virol. 2003 Mar;77(6):3809-15 [12610155.001]
  • [Cites] J Virol. 2003 Apr;77(7):4205-20 [12634378.001]
  • [Cites] EMBO Rep. 2003 Jun;4(6):609-15 [12776180.001]
  • [Cites] Virology. 2004 Jan 20;318(2):542-55 [14972523.001]
  • [Cites] J Virol. 2004 Apr;78(7):3601-20 [15016882.001]
  • [Cites] Virology. 2004 Aug 1;325(2):225-40 [15246263.001]
  • [Cites] J Virol. 2004 Oct;78(19):10657-73 [15367633.001]
  • [Cites] Oncogene. 2004 Oct 28;23(50):8272-81 [15467747.001]
  • [Cites] J Virol. 1990 Mar;64(3):1143-55 [2154599.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] J Virol. 1996 Jan;70(1):549-58 [8523568.001]
  • (PMID = 19321621.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic-Leucine Zipper Transcription Factors; 0 / K8 protein, Human herpesvirus 8; 0 / RNA, Messenger; 0 / Repressor Proteins; 0 / Viral Proteins
  • [Other-IDs] NLM/ PMC2681977
  •  go-up   go-down


86. Katsnel'son BA, Kuz'min SV, Gurvich VB: [The concept of acceptable risk is the key debatable issue of the assessment and management of a risk to the population's health]. Gig Sanit; 2007 May-Jun;(3):76-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The concept of acceptable risk is the key debatable issue of the assessment and management of a risk to the population's health].
  • They criticize the sociostatistical and socioeconomic concepts of risk acceptability as both amoral and impracticable and propose an approach based on the use of the Russian standards of permissible exposure levels (maximum permissible concentrations in particular) and on the exposure-response relationships established by epidemiological studies for the computation of responses (i.e. risk levels) corresponding to the permissible exposures.
  • In some cases that such standards of an acceptable risk are too strict in existing technological or economic practice may be introduced in a stepwise fashion, but the risks that exceed the acceptable level should be compensated for.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17658052.001).
  • [ISSN] 0016-9900
  • [Journal-full-title] Gigiena i sanitariia
  • [ISO-abbreviation] Gig Sanit
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


87. Leto TL, Lavigne MC, Homoyounpour N, Lekstrom K, Linton G, Malech HL, de Mendez I: The K-562 cell model for analysis of neutrophil NADPH oxidase function. Methods Mol Biol; 2007;412:365-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Polymorphonuclear neutrophils (PMN) have a remarkable capacity for generation of large amounts of reactive oxygen species in response to a variety of infectious or inflammatory stimuli, a process known as the respiratory burst that involves activation of a multicomponent NADPH oxidase.
  • We have explored a variety of methods for introduction of components of the phagocytic oxidase (phox system) into the promyelocytic erythroleukemia cell line, K-562.
  • These versatile lines can be used to examine effects of genetic polymorphisms or mutations in phox components associated with chronic granulomatous disease, to serve as a system for testing gene therapy vectors designed to correct the defective oxidase, to study cross-functioning with recently described phox component homologs, or to explore signaling components involved in regulation of the respiratory burst.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18453124.001).
  • [ISSN] 1064-3745
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.6.3.1 / NADPH Oxidase
  •  go-up   go-down


88. Santiago-Doménech N, Jiménez-Bemúdez S, Matas AJ, Rose JK, Muñoz-Blanco J, Mercado JA, Quesada MA: Antisense inhibition of a pectate lyase gene supports a role for pectin depolymerization in strawberry fruit softening. J Exp Bot; 2008;59(10):2769-79
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antisense inhibition of a pectate lyase gene supports a role for pectin depolymerization in strawberry fruit softening.
  • It has been reported previously that inhibiting the expression of pectate lyase genes by antisense technology in strawberry (Fragaria x ananassa Duch.) fruit resulted in prolonged fruit firmness.
  • In this present study, three independent transgenic lines were identified exhibiting a greater than 90% reduction in pectate lyase transcript abundance.
  • These results indicate that pectate lyase plays an important degradative role in the primary wall and middle lamella in ripening strawberry fruit, and should be included in synergistic models of cell wall disassembly.

  • Hazardous Substances Data Bank. PECTIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Bot. 2001 Aug;52(361):1635-45 [11479328.001]
  • [Cites] Plant Mol Biol. 2001 Sep;47(1-2):311-40 [11554479.001]
  • [Cites] Planta. 2001 Nov;214(1):11-21 [11762160.001]
  • [Cites] Planta. 2001 Dec;214(2):257-64 [11800390.001]
  • [Cites] Plant Physiol. 2002 Feb;128(2):751-9 [11842178.001]
  • [Cites] J Exp Bot. 2002 Oct;53(377):2115-9 [12324535.001]
  • [Cites] Plant Physiol. 2007 Aug;144(4):1693-6 [17687051.001]
  • [Cites] Planta. 2003 Oct;217(6):951-61 [12838420.001]
  • [Cites] Plant Physiol. 1997 Jul;114(3):1071-6 [9232883.001]
  • [Cites] Plant Mol Biol. 1997 Aug;34(6):867-77 [9290639.001]
  • [Cites] Anal Biochem. 1998 Mar 15;257(2):107-11 [9514779.001]
  • [Cites] Plant Physiol Biochem. 2004 Dec;42(10):823-31 [15596102.001]
  • [Cites] Plant Physiol. 2007 Jun;144(2):1012-28 [17449643.001]
  • [Cites] J Exp Bot. 2003 Feb;54(383):633-45 [12554706.001]
  • (PMID = 18522930.001).
  • [ISSN] 1460-2431
  • [Journal-full-title] Journal of experimental botany
  • [ISO-abbreviation] J. Exp. Bot.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Pectins; 0 / Plant Proteins; 9000-69-5 / pectin; EC 4.2.2.- / Polysaccharide-Lyases; EC 4.2.2.2 / pectate lyase
  • [Other-IDs] NLM/ PMC2486476
  • [Keywords] NOTNLM ; Cell wall / Fragaria / fruit ripening / pectate lyase / pectinases / strawberry
  •  go-up   go-down


89. Wang Y, Fiskus W, Chong DG, Buckley KM, Natarajan K, Rao R, Joshi A, Balusu R, Koul S, Chen J, Savoie A, Ustun C, Jillella AP, Atadja P, Levine RL, Bhalla KN: Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood; 2009 Dec 3;114(24):5024-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells.
  • PS also induced apoptosis of the cultured JAK2V617F-expressing human erythroleukemia HEL92.1.7 and Ba/F3-JAK2V617F cells.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2008 Oct;22(10):1828-40 [18769448.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2190-8 [18779404.001]
  • [Cites] J Biol Chem. 2008 Nov 21;283(47):32334-43 [18775810.001]
  • [Cites] Blood. 2009 Mar 26;113(13):2895-901 [18988864.001]
  • [Cites] Cancer Biol Ther. 2009 May;8(10):939-50 [19279403.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Mar 2;281(3):663-9 [11237709.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Sep;3(9):651-62 [12209125.001]
  • [Cites] Blood. 2002 Oct 15;100(8):3041-4 [12351420.001]
  • [Cites] Adv Enzyme Regul. 1984;22:27-55 [6382953.001]
  • [Cites] J Immunol. 1999 Nov 1;163(9):4909-16 [10528193.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1768-76 [15514006.001]
  • [Cites] Lancet. 2005 Mar 19-25;365(9464):1054-61 [15781101.001]
  • [Cites] Mol Cancer Res. 2005 Mar;3(3):170-81 [15798097.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):387-97 [15837627.001]
  • [Cites] Nature. 2005 Apr 28;434(7037):1144-8 [15793561.001]
  • [Cites] J Biol Chem. 2005 Jul 22;280(29):26729-34 [15937340.001]
  • [Cites] Blood. 2006 Jan 1;107(1):293-300 [16150941.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):18962-7 [16365288.001]
  • [Cites] Nat Rev Cancer. 2006 Jan;6(1):38-51 [16397526.001]
  • [Cites] Blood. 2006 Jul 15;108(2):645-52 [16537804.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1652-60 [16670266.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11156-65 [17145859.001]
  • [Cites] PLoS One. 2006;1:e18 [17183644.001]
  • [Cites] N Engl J Med. 2007 Feb 1;356(5):459-68 [17267906.001]
  • [Cites] J Mol Diagn. 2007 Apr;9(2):242-8 [17384217.001]
  • [Cites] Blood. 2007 Jul 15;110(2):678-85 [17395781.001]
  • [Cites] Leukemia. 2007 Aug;21(8):1658-68 [17541402.001]
  • [Cites] Nat Rev Cancer. 2007 Sep;7(9):673-83 [17721432.001]
  • [Cites] Mol Cancer Ther. 2007 Sep;6(9):2515-24 [17876048.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2242-9 [17496200.001]
  • [Cites] Oncogene. 2007 Oct 15;26(47):6724-37 [17934481.001]
  • [Cites] Leukemia. 2008 Jan;22(1):14-22 [17882280.001]
  • [Cites] Leukemia. 2008 Jan;22(1):23-30 [17882282.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1686-9 [17984312.001]
  • [Cites] Leukemia. 2008 Mar;22(3):474-86 [18185525.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3751-9 [18216297.001]
  • [Cites] Cancer Cell. 2008 Apr;13(4):311-20 [18394554.001]
  • [Cites] Cancer Cell. 2008 Apr;13(4):321-30 [18394555.001]
  • [Cites] Leukemia. 2008 Apr;22(4):740-7 [18079739.001]
  • [Cites] Cell Cycle. 2008 Mar 15;7(6):714-9 [18245948.001]
  • [Cites] J Biol Chem. 2008 May 9;283(19):12941-8 [18326042.001]
  • [Cites] Blood. 2008 May 15;111(10):5109-17 [18334677.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4833-42 [18559531.001]
  • [Cites] Leukemia. 2008 Jul;22(7):1320-34 [18528425.001]
  • [Cites] Blood. 2008 Aug 15;112(4):1402-12 [18515659.001]
  • [Cites] Leukemia. 2008 Nov;22(11):2011-9 [18923436.001]
  • (PMID = 19828702.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA116629; United States / NCI NIH HHS / CA / R01 CA123207
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Hydroxamic Acids; 0 / Indoles; 0 / Pyrimidines; 0 / Sulfonamides; 0 / TG101209; 9647FM7Y3Z / panobinostat; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  • [Other-IDs] NLM/ PMC2788976
  •  go-up   go-down


90. Ambrose EC, Kornbluth J: Downregulation of uridine-cytidine kinase like-1 decreases proliferation and enhances tumor susceptibility to lysis by apoptotic agents and natural killer cells. Apoptosis; 2009 Oct;14(10):1227-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we use RNA interference to downregulate UCKL-1 expression in K562 erythroleukemia cells.
  • [MeSH-minor] Caspase 3 / metabolism. Caspase 7 / metabolism. Cell Cycle / drug effects. Cell Proliferation / drug effects. Etoposide / pharmacology. Gene Expression Regulation, Neoplastic / drug effects. Gene Silencing / drug effects. Green Fluorescent Proteins / metabolism. Humans. K562 Cells. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Small Interfering / metabolism. Staurosporine / pharmacology. Time Factors

  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19653100.001).
  • [ISSN] 1573-675X
  • [Journal-full-title] Apoptosis : an international journal on programmed cell death
  • [ISO-abbreviation] Apoptosis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Small Interfering; 147336-22-9 / Green Fluorescent Proteins; 6PLQ3CP4P3 / Etoposide; EC 2.7.1.48 / UCKL-1 protein, human; EC 2.7.1.48 / Uridine Kinase; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 7; H88EPA0A3N / Staurosporine
  •  go-up   go-down


91. Chen H, Ding XY, Gao Y, Liu XL, Gao JE, Sun QH: [Recombinant human VEGF-D induces the angiogenesis of the chick embryo chorioallantoic membrane]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Apr;15(2):364-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The soluble GST-VEGF-D fusion protein could interact with VEGFR-3/Fc and was able to stimulate the proliferation of human erythroleukemia cell line (HEL) cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17493348.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Recombinant Proteins; 0 / Vascular Endothelial Growth Factor D
  •  go-up   go-down


92. Saar K, Lindgren M, Hansen M, Eiríksdóttir E, Jiang Y, Rosenthal-Aizman K, Sassian M, Langel U: Cell-penetrating peptides: a comparative membrane toxicity study. Anal Biochem; 2005 Oct 1;345(1):55-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therefore, we investigated membrane toxicity of five peptides with well-documented cell-penetrating properties, pAntp(43-58), pTAT(48-60), pVEC(615-632), model amphipathic peptide (MAP), and transportan 10, on two human cancer cell lines, K562 (erythroleukemia) and MDA-MB-231 (breast cancer), as well as on immortalized aortic endothelial cells.
  • MAP and transportan 10 caused significant leakage; in K562 and MDA-MB-231 cells, 40% of total lactate dehydrogenase leaked out during 10 min exposure to 10 microM of transportan 10 and MAP, accompanied by a significant increase in bis-oxonol fluorescence.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16137634.001).
  • [ISSN] 0003-2697
  • [Journal-full-title] Analytical biochemistry
  • [ISO-abbreviation] Anal. Biochem.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drug Carriers; 0 / Peptides
  •  go-up   go-down


93. Shaked Y, Emmenegger U, Francia G, Chen L, Lee CR, Man S, Paraghamian A, Ben-David Y, Kerbel RS: Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res; 2005 Aug 15;65(16):7045-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, whereas surprisingly durable and potent tumor responses have been observed in a number of preclinical tumor models, relapses usually eventually occur using this type of treatment strategy.
  • Here, we show that repeated administration of bolus doses (BDs) of cyclophosphamide every 3 or 6 weeks, combined with a daily oral low-dose metronomic (LDM) regimen (20 mg/kg/d cyclophosphamide), improves efficacy and significantly delays progression of transplanted PC-3 human prostate cancer xenografts, syngeneic transplanted EMT-6 breast tumors, and "spontaneous" murine erythroleukemia.
  • Efficacy was superior whereas toxicity was mild and comparable to the LDM regimen, the latter assessed by body weight, neutrophil, lymphocyte, and total white blood counts.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Cyclophosphamide / administration & dosage. Leukemia, Erythroblastic, Acute / drug therapy. Mammary Neoplasms, Experimental / drug therapy. Prostatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16103050.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-41233
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


94. Eilertsen GØ, Nossent JC: Erythroleukaemia complicating ANA-negative systemic lupus erythematosus. Scand J Rheumatol; 2007 Nov-Dec;36(6):478-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erythroleukaemia complicating ANA-negative systemic lupus erythematosus.
  • [MeSH-major] Antibodies, Antinuclear / blood. Leukemia, Erythroblastic, Acute / etiology. Lupus Erythematosus, Systemic / complications

  • Genetic Alliance. consumer health - Lupus.
  • Genetic Alliance. consumer health - Systemic lupus erythematosus.
  • MedlinePlus Health Information. consumer health - Lupus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18092272.001).
  • [ISSN] 0300-9742
  • [Journal-full-title] Scandinavian journal of rheumatology
  • [ISO-abbreviation] Scand. J. Rheumatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear
  •  go-up   go-down


95. Parry TE: On the pathogenesis of erythroleukaemia (H0493). Leuk Res; 2005 Feb;29(2):119-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] On the pathogenesis of erythroleukaemia (H0493).
  • In erythroleukaemia megaloblastic changes can co-exist with leukaemic changes in the marrow.
  • The cause of the disease must therefore be such as can cause megaloblastosis and at the same time be mutagenic.
  • Failure of the thymidylate synthelase reaction, the commonest cause of megaloblastic anaemia, can be eliminated in erythroleukaemia because (a) the dU suppression test is normal in the disease and (b) failure of the thymidylate synthelase reaction is not mutagenic.
  • The deamination of both cytosine and adenine is mutagenic but the deamination of cytosine alone is apparent and the nucleotide of cytosine is the prime mutagenic nucleotide in leukaemia and cancer.
  • Megaloblastic changes can result from an inadequate supply of any one of the four nucleotides that enter into the composition of DNA and it is suggested that an inadequate supply of the mutagenic nucleotide of cytosine, possibly through impaired synthesis, could cause both the megaloblastic and leukaemic changes in erythroleukaemia.
  • [MeSH-major] Leukemia, Erythroblastic, Acute / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15607356.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Nucleotides; 9007-49-2 / DNA; EC 2.1.1.45 / Thymidylate Synthase
  • [Number-of-references] 22
  •  go-up   go-down


96. Mohan SV, Mouli PC: Assessment of aerosol (PM10) and trace elemental interactions by Taguchi experimental design approach. Ecotoxicol Environ Saf; 2008 Mar;69(3):562-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Seven toxic trace metals (Cu, Cd, As, Pb, Cr, Co and Ni) along with aerosol mass (PM(10)) at three different concentration levels were considered for this study.
  • The annual mean concentrations of PM(10) and its trace components observed at Tirupati, southern peninsular India, and 50% lower and 50% higher values to the permissible exposure limit (PEL) of each factor in air were considered for level 1, level 2, and level 3 respectively.
  • Interactions between the factors have been estimated by orthogonal array design of experiments with eighteen sets of experimental trial (L18) and varied combinations of factor levels.

  • Hazardous Substances Data Bank. Lead, elemental .
  • Hazardous Substances Data Bank. NICKEL, ELEMENTAL .
  • Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .
  • Hazardous Substances Data Bank. CHROMIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. COBALT, ELEMENTAL .
  • Hazardous Substances Data Bank. COPPER, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17490743.001).
  • [ISSN] 0147-6513
  • [Journal-full-title] Ecotoxicology and environmental safety
  • [ISO-abbreviation] Ecotoxicol. Environ. Saf.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aerosols; 0 / Trace Elements; 0R0008Q3JB / Chromium; 2P299V784P / Lead; 3G0H8C9362 / Cobalt; 789U1901C5 / Copper; 7OV03QG267 / Nickel; N712M78A8G / Arsenic
  •  go-up   go-down


97. Bavelloni A, Faenza I, Cioffi G, Piazzi M, Parisi D, Matic I, Maraldi NM, Cocco L: Proteomic-based analysis of nuclear signaling: PLCbeta1 affects the expression of the splicing factor SRp20 in Friend erythroleukemia cells. Proteomics; 2006 Nov;6(21):5725-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic-based analysis of nuclear signaling: PLCbeta1 affects the expression of the splicing factor SRp20 in Friend erythroleukemia cells.
  • Constitutive overexpression of nuclear PLCbeta(1) has been previously shown to inhibit Friend erythroleukemia cells differentiation and to induce cell cycle progression targeting cyclin D3.
  • To identify novel downstream effectors of nuclear PLCbeta(1)-dependent signaling in Friend erythroleukemia cells, we performed the high-resolution 2-DE-based proteomic analysis.
  • Using a proteomic approach we found that SRp20, a member of the highly conserved SR family of splicing regulators, was down-regulated in cells overexpressing nuclear PLCbeta(1) as compared with wild-type cells.
  • Here we show the existence of a PLCbeta(1)-specific target, the splicing factor SRp20, whose expression is specifically down-regulated by the nuclear signaling evoked by PLCbeta(1).
  • [MeSH-major] Cell Nucleus / metabolism. Isoenzymes / metabolism. Leukemia, Erythroblastic, Acute / metabolism. Proteomics / methods. RNA-Binding Proteins / metabolism. Signal Transduction. Type C Phospholipases / metabolism
  • [MeSH-minor] Animals. Blotting, Western. Cells, Cultured. Down-Regulation. Electrophoresis, Gel, Two-Dimensional. Fluorescein-5-isothiocyanate. Fluorescent Antibody Technique, Direct. Fluorescent Dyes. Gene Expression Regulation, Neoplastic. Isoelectric Focusing. Mice. Microscopy, Fluorescence. Peptide Mapping. Phospholipase C beta. Precipitin Tests. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. Subcellular Fractions / metabolism


98. Rongies W, Bak A, Lazar A, Dolecki W, Kolanowska-Kenczew T, Sierdziński J, Spychała A, Krakowiecki A: A trial of the use of pedobarography in the assessment of the effectiveness of rehabilitation in patients with coxarthrosis. Ortop Traumatol Rehabil; 2009 May-Jun;11(3):242-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of the study was to assess the progress of a selected model of rehabilitation on the basis of subpedal pressure distribution and centre of gravity sway in pedobarographic examination as well as to evaluate changes in pain intensity in patients with a history of coxarthrosis.
  • A postural pedobarographic examination was performed immediately before and after a 15-day course of rehabilitation with a PEL 38 electronic pedobarograph and computer image analyser with TWINN 99 software, version 2.08.
  • 2. The pedobarographic examination may become a new method of diagnosis and follow-up in rehabilitation.

  • MedlinePlus Health Information. consumer health - Foot Health.
  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620742.001).
  • [ISSN] 1509-3492
  • [Journal-full-title] Ortopedia, traumatologia, rehabilitacja
  • [ISO-abbreviation] Ortop Traumatol Rehabil
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


99. Rimmelé P, Kosmider O, Mayeux P, Moreau-Gachelin F, Guillouf C: Spi-1/PU.1 participates in erythroleukemogenesis by inhibiting apoptosis in cooperation with Epo signaling and by blocking erythroid differentiation. Blood; 2007 Apr 1;109(7):3007-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spi-1/PU.1 participates in erythroleukemogenesis by inhibiting apoptosis in cooperation with Epo signaling and by blocking erythroid differentiation.
  • Overexpression of the transcription factor Spi-1/PU.1 in mice leads to acute erythroleukemia characterized by a differentiation block at the proerythroblastic stage.
  • In this study, we made use of a new cellular system allowing us to reach graded expression of Spi-1 in preleukemic cells to dissect mechanisms of Spi-1/ PU-1 in erythroleukemogenesis.
  • We show that Spi-1 knock-down was sufficient to reinstate the erythroid differentiation program.
  • Evidence is provided that in the presence of erythropoietin (Epo), Spi-1 displays an antiapoptotic role that is independent of its function in blocking erythroid differentiation.
  • Furthermore, we found that reducing the Spi-1 level yields to ERK dephosphorylation and increased phosphorylation of AKT and STAT5, suggesting that Spi-1 may affect major signaling pathways downstream of the EpoR in erythroid cells.
  • These findings reveal 2 distinct roles for Spi-1 during erythroleukemogenesis: Spi-1 blocks the erythroid differentiation program and acts to impair apoptotic death in cooperation with an Epo signaling.
  • [MeSH-major] Erythropoietin / physiology. Leukemia, Erythroblastic, Acute / etiology. Proto-Oncogene Proteins / physiology. Trans-Activators / physiology

  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17132716.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; 0 / RNA, Small Interfering; 0 / Receptors, Erythropoietin; 0 / Trans-Activators; 0 / proto-oncogene protein Spi-1; 11096-26-7 / Erythropoietin
  •  go-up   go-down


100. Kakooei H, Sameti M, Kakooei AA: Asbestos exposure during routine brake lining manufacture. Ind Health; 2007 Dec;45(6):787-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asbestos exposure during routine brake lining manufacture.
  • Occupational exposure to asbestos fiber and total dust of workers of a major brake lining manufacture plant in a developing country were examined and compared with those in developed countries.
  • Time weighted average of total dust and asbestos fiber concentration in the potential sources of exposure were monitored.
  • All personal air sampling were collected on membrane filters and analyzed by phase contrast optical microscopy (PCM) for comparison with the occupational safety and health administration (OSHA) permissible exposure limit (PEL) of 0.1 f/cc, 8-h time--weighted average.
  • This study demonstrates that routine mixing, polishing and beveling process in the brake lining production can result in elevated levels of airborne asbestos.
  • The results also showed that the employees working in the process had the exposure to total dust concentrations ranging from 2.08 to 16.32 mg/m(3) that is higher than OSHA, recommendation.
  • During an 8-h shift, the average asbestos fiber exposure (0.78 f/cc) were 7.8 time in excess of OSHA PEL.
  • Additional studies in occupational exposure to asbestos are needed.
  • [MeSH-major] Air Pollutants, Occupational / analysis. Asbestos / analysis. Dust / analysis. Environmental Monitoring / methods. Manufactured Materials. Occupational Exposure / analysis

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18212474.001).
  • [ISSN] 0019-8366
  • [Journal-full-title] Industrial health
  • [ISO-abbreviation] Ind Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Air Pollutants, Occupational; 0 / Dust; 1332-21-4 / Asbestos
  •  go-up   go-down






Advertisement